# EDGAR Filing Document

**Accession Number:** 0001130166
**File Stem:** 0001641172-25-016520
**Filing Date:** 2025-6
**Character Count:** 187199
**Document Hash:** 428c9a58b22011785a8d3b7ab5acf0f9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-016520.hdr.sgml**: 20250625

**ACCESSION NUMBER**: 0001641172-25-016520

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20250625

**DATE AS OF CHANGE**: 20250625

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cyclacel Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001130166
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911766850
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-50626
- **FILM NUMBER:** 251074555

**BUSINESS ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922
- **BUSINESS PHONE:** 908-517-7330

**MAIL ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XCYTE THERAPIES INC
- **DATE OF NAME CHANGE:** 20001218

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**AMENDMENT NO. 1**

**TO**

**SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

**☐** **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under Rule 14a-12

**CYCLACEL PHARMACEUTICALS, INC.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

EXPLANATORY NOTE

This Amendment No. 1 to Schedule 14A (the "Amendment") is being filed to amend Cyclacel Pharmaceutical, Inc.'s (the "Company") definitive proxy statement for its 2025 Annual Meeting of Shareholders (the "Proxy Statement"), which was filed with the Securities and Exchange Commission on April 24, 2025. The Amendment corrects (on pages 2 and 7) a scrivener's error in total shares outstanding from 381,202,294 to 356,357,531 shares outstanding on the record date. No other changes have been made to the Proxy Statement or to the matters to be considered by the stockholders. All other items of the Proxy Statement are incorporated herein by reference without change.

**CYCLACEL PHARMACEUTICALS, INC.**

**Level 10, Tower 11, Avenue 5, No. 8**

**Jalan Kerinchi, Kuala Lumpur, Malaysia 59200**

April 24, 2025

To Our Stockholders:

You are cordially invited to attend the 2025 Annual Meeting of Stockholders of Cyclacel Pharmaceuticals, Inc. (the "**Company**") to be held at 10:00 a.m., E.D.T., on June 30, 2025. We have decided to hold this year's annual meeting via live audio webcast on the internet (the "**Meeting**"). We believe hosting a virtual annual meeting enables greater stockholder attendance and participation from any location around the world, improves meeting efficiency and our ability to communicate effectively with our stockholders, and reduces the cost and environmental impact of our annual meeting. You will be able to attend the annual meeting, vote and submit your questions during the annual meeting by visiting www.proxyvote.com. You will not be able to attend the annual meeting in person.

The attached Notice of Annual Meeting and proxy statement describe the business we will conduct at the annual meeting and provide information about us that the holders of our common stock (the "**Common Stock**") should consider when voting.

At the annual meeting, we will ask our holders of Common Stock to:

&nbsp;&nbsp;&nbsp;&nbsp;1. re-elect
 each of Datuk Dr. Doris Wong, Kiu Cu Seng, Kwang Fock Chong, Dr. Satis Waran Nair Krishnan, and Inigo Angel Laurduraj, nominees to
 our Board of Directors;

2. approve
 a proposed amendment to the Company's 2018 Equity Incentive Plan to increase the number of shares of Common Stock available
 for the grant of awards by 4,281,987 shares; and

3. approve
 by an advisory vote the compensation of our named executive officers and directors, as disclosed in this proxy statement.

In addition, our holders of Common Stock shall consider and act upon such other business and matters as may properly come before the Meeting or any adjournments thereof. The Board of Directors recommends the approval of each of these proposals.

Under Securities and Exchange Commission rules that allow companies to furnish proxy materials to stockholders over the Internet, we have elected to deliver our proxy materials to the majority of our stockholders over the Internet. This delivery process allows us to provide stockholders with the information they need, while at the same time conserving natural resources and lowering the cost of delivery. On or about May 16, 2025, we will commence mailing to our stockholders a Notice of Internet Availability of Proxy Materials (the "**Notice**") containing instructions on how to access our proxy statement for our 2025 Annual Meeting of Stockholders and our 2024 annual report to stockholders. The Notice also provides instructions on how to vote online or by telephone, how to access the virtual annual meeting and how to receive a paper copy of the proxy materials by mail.

We hope you will be able to attend the annual meeting. Whether you plan to attend the annual meeting or not, it is important that you cast your vote either at the meeting or by proxy. You may vote over the Internet as well as by telephone or by mail. Therefore, when you have finished reading the proxy statement, you are urged to vote in accordance with the instructions set forth in this proxy statement. We encourage you to vote by proxy so that your shares will be represented and voted at the annual meeting, whether or not you can attend.

Thank you for your ongoing support of Cyclacel Pharmaceuticals, Inc. We look forward to seeing you at the annual meeting.

Sincerely,

*/s/ Datuk Dr. Doris Wong*

 

Datuk Dr. Doris Wong

Chief Executive Officer and Executive Director

**CYCLACEL PHARMACEUTICALS, INC.**

**Level 10, Tower 11, Avenue 5, No. 8**

**Jalan Kerinchi, Kuala Lumpur, Malaysia 59200**

**April 24, 2025**

**NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS**

---

| | |
|:---|:---|
| ***Time:*** | 10:00 a.m. E.D.T |
| ***Date:*** | June 30, 2025 |
| ***Access:*** | This year's annual meeting will be a virtual meeting via live audio webcast on the Internet. You will be able to attend the annual meeting, vote and submit your questions during the meeting by visiting www.proxyvote.com and entering the 16-digit control number included in the Notice of Internet Availability or proxy card that you receive. For further information about the virtual annual meeting, please see the Questions and Answers about the Meeting beginning on page 2 of the accompanying proxy statement. |
| ***Purposes:*** | For the holders of our common stock ("**Common Stock**"): |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. re-elect
 each of Datuk Dr. Doris Wong (to Class 3), Kiu Cu Seng (to Class 2), Kwang Fock Chong (to Class 2), Dr. Satis Waran Nair Krishnan
 (to Class 1), and Inigo Angel Laurduraj (to Class 1), nominees to our Board of Directors;

2. approve
 a proposed amendment to the Company's 2018 Equity Incentive Plan to increase the number of shares of Common Stock available
 for the grant of awards by 4,281,987 shares; and

3. approve
 by an advisory vote the compensation of our named executive officers and directors, as disclosed in this proxy statement.

In addition, our holders of Common Stock shall consider and act upon such other business and matters as may properly come before the Meeting or any adjournments thereof. The Board of Directors recommends the approval of each of these proposals.

**WHO MAY VOTE?**

You may vote if you were the record holder of our Common Stock at the close of business on May 1, 2025. A list of stockholders of record will be available at the annual meeting and during the ten days prior to the annual meeting at the office of our Secretary at the above address.

All stockholders are cordially invited to attend the annual meeting. **Whether you plan to attend the annual meeting or not, we urge you to vote by following the instructions in the Notice of Internet Availability of Proxy Materials that you previously received and submit your proxy by the Internet, telephone or mail in order to ensure the presence of a quorum**. You may change or revoke your proxy at any time before it is voted at the meeting. If you participate in and vote your shares at the annual meeting, your proxy will not be used.

By order of the Board of Directors

*/s/ Kiu Cu Seng*

 

Kiu Cu Seng, Secretary

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | Page |
| [IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE SHAREHOLDER MEETING TO BE HELD ON JUNE 30, 2025](#a_001) | 1 |
| [IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING](#a_002) | 2 |
| [SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT](#a_003) | 7 |
| [MANAGEMENT AND CORPORATE GOVERNANCE](#a_004) | 9 |
| [EXECUTIVE AND DIRECTOR COMPENSATION](#a_005) | 14 |
| [EQUITY COMPENSATION PLAN INFORMATION](#a_006) | 16 |
| [PAY VERSUS PERFORMANCE](#a_007) | 19 |
| [REPORT OF AUDIT COMMITTEE](#a_008) | 21 |
| [CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS](#a_009) | 22 |
| [PROPOSALS TO BE VOTED UPON BY HOLDERS OF COMMON STOCK](#a_010) | 23 |
| [PROPOSAL 1: ELECTION OF CLASS DIRECTORS](#a_011) | 23 |
| [PROPOSAL 2: AMENDMENT TO 2018 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE FOR THE GRANT OF AWARDS BY 4,281,987 SHARES](#a_012)<br>| 24 |
| [PROPOSAL 3: ADVISORY VOTE ON APPROVAL OF EXECUTIVE COMPENSATION AS DISCLOSED IN THIS PROXY STATEMENT](#a_013) | 29 |
| [CODE OF CONDUCT AND ETHICS](#a_014) | 30 |
| [OTHER MATTERS](#a_015) | 30 |
| [STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR](#a_016) | 30 |
| [APPENDIX A: 2018 EQUITY INCENTIVE PLAN, AS AMENDED](#a_017) | A-1 |

---

**CYCLACEL PHARMACEUTICALS, INC.**

**Level 10, Tower 11, Avenue 5, No. 8**

**Jalan Kerinchi, Kuala Lumpur, Malaysia 59200**

**PROXY STATEMENT FOR CYCLACEL PHARMACEUTICALS, INC.**

**2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 30, 2025**

This proxy statement, along with the accompanying notice of the 2025 Annual Meeting of stockholders, contains information about the 2025 Annual Meeting of stockholders of Cyclacel Pharmaceuticals, Inc., including any adjournments or postponements of the annual meeting. This year's annual meeting will be held via live audio webcast on the internet. You will be able to participate, vote and submit your questions during the annual meeting by visiting www.proxyvote.com. You will not be able to attend the annual meeting physically.

In this proxy statement, we refer to Cyclacel Pharmaceuticals, Inc. as "Cyclacel," "the Company," "we" and "us."

This proxy statement relates to the solicitation of proxies by our Board of Directors for use at the annual meeting.

**On or about May 16, 2025, we intend to begin sending to our stockholders the Important Notice Regarding the Availability of Proxy Materials containing instructions on how to access our proxy statement for our 2025 Annual Meeting of stockholders and our 2024 annual report to stockholders.**

**____________________________**

**IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE**

**SHAREHOLDER MEETING TO BE HELD ON JUNE 30, 2025**

**This proxy statement, the notice of 2025 Annual Meeting of stockholders, our form of proxy card and our 2024 annual report to stockholders are available for viewing, printing and downloading at www.proxyvote.com. To view these materials, please have your 16-digit control number(s) available that appears on your Internet Availability Notice or proxy card. On this website, you can also elect to receive future distributions of our proxy statements and annual reports to stockholders by electronic delivery.**

**Additionally, you can find a copy of our Annual Report on Form 10-K, which includes our financial statements, for the fiscal year ended December 31, 2024 on the website of the Securities and Exchange Commission, or the SEC, at www.sec.gov, or in the "SEC Filings" section of the "Investors" section of our website at www.cyclacel.com.**

**You may also obtain a printed copy of our Annual Report on Form 10-K, including our financial statements, free of charge, from us by sending a written request to: Cyclacel Pharmaceuticals, Inc., Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 59200, attention: Secretary, Annual Meeting. Exhibits will be provided upon written request and payment of an appropriate processing fee.**

**IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING**

**Why is the Company Soliciting My Proxy?**

The Board of Directors of Cyclacel is soliciting your proxy to vote at the 2025 Annual Meeting of stockholders, and any adjournments or postponements of the meeting, which we refer to as the annual meeting, to be held at 10:00 a.m., E.D.T., on June 30, 2025. This year's annual meeting will be held via live audio webcast on the internet. You will be able to participate, vote and submit your questions during the annual meeting by visiting www.proxyvote.com. If you encounter any difficulties accessing the virtual meeting during check-in or the meeting, please call the technical support number that will be posted on the virtual shareholder meeting log-in page. We believe that a virtual meeting will provide expanded stockholder access and participation and improved communications. You will not be able to attend the annual meeting physically. The proxy statement, along with the accompanying Notice of Annual Meeting of Stockholders, summarizes the purposes of the meeting and the information you need to know to vote at the annual meeting.

We have made available to you on the Internet or have sent you this proxy statement, the 2025 notice of annual meeting of stockholders, the proxy card or cards and a copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 because you owned shares of our common stock ("**Common Stock**") on the record date. We intend to commence distribution of the Important Notice Regarding the Availability of Proxy Materials, which we refer to throughout this proxy statement as the Internet Availability Notice, and, if applicable, proxy materials to stockholders on or about May 16, 2025.

**Why Did I Receive a Notice in the Mail Regarding the Internet Availability of Proxy Materials Instead of a Full Set of Proxy Materials?**

As permitted by the rules of the U.S. Securities and Exchange Commission (the "**SEC**"), we may furnish our proxy materials to our stockholders by providing access to such documents on the Internet, rather than mailing printed copies of these materials to each stockholder. Most stockholders will not receive printed copies of the proxy materials unless they request them. We believe that this process should expedite stockholders' receipt of proxy materials, lower the costs of the annual meeting and help to conserve natural resources. If you receive the Internet Availability Notice by mail or electronically, you will not receive a printed or email copy of the proxy materials, unless you request one by following the instructions included in the Internet Availability Notice. Instead, the Internet Availability Notice instructs you as to how you may access and review all of the proxy materials and submit your proxy on the Internet. If you requested a paper copy of the proxy materials, you may authorize the voting of your shares by following the instructions on the proxy card, in addition to the other methods of voting described in this proxy statement.

**Why Are You Holding a Virtual Annual Meeting?**

This year's annual meeting will be held in a virtual meeting format only. We have designed our virtual format to enhance, rather than constrain, stockholder access, participation and communication. For example, the virtual format allows stockholders to communicate with us in advance of, and during, the annual meeting so they can ask questions of our board of directors or management, as time permits.

**How do I access the Virtual Annual Meeting?**

The live webcast of the Annual Meeting will begin promptly at 10:00 a.m. E.D.T. Online access to the audio webcast will open 15 minutes prior to the start of the Annual Meeting to allow time for you to log-in and test your device's audio system. The virtual Annual Meeting is running the most updated version of the applicable software and plugins. You should ensure you have a strong internet connection wherever you intend to participate in the Annual Meeting. You should also allow plenty of time to log in and ensure that you can hear streaming audio prior to the start of the Annual Meeting.

Log-in Instructions. To be admitted to the virtual Annual Meeting, you will need to log-in at www.proxyvote.com using the 16-digit control number found on the proxy card or voting instruction card previously mailed or made available to stockholders entitled to vote at the Annual Meeting.

**Who May Vote?**

Only stockholders who own our Common Stock at the close of business on May 1, 2025 will be entitled to vote at the annual meeting. On this record date, there were 356,357,531 shares of our Common Stock outstanding and entitled to vote on the proposals submitted to our holders of Common Stock.

If on May 1, 2025 your shares of our Common Stock were registered directly in your name with our transfer agent, Equiniti Trust Company, LLC, then you are a stockholder of record.

If on May 1, 2025 your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in "street name" and the Internet Availability Notice or if applicable, our proxy materials are being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the annual meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend the annual meeting. However, since you are not the stockholder of record, you may not vote your shares at the annual meeting unless you request and obtain a valid proxy from your broker or other agent.

You do not need to attend the annual meeting to vote your shares. Shares represented by valid proxies, received in time for the annual meeting and not revoked prior to the annual meeting, will be voted at the annual meeting. For instructions on how to change or revoke your proxy, see "*May I Change or Revoke My Proxy?*" below.

For the ten-day period immediately prior to the annual meeting, the list of the stockholders of record entitled to vote at the annual meeting will be available for inspection at our offices at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 59200, by stockholders for such purposes as are set forth in the General Corporation Law of the State of Delaware. The list of the stockholders will also be available for inspection at the annual meeting.

**What Proposals Can I Vote on as a Holder of Preferred Stock?**

The holders of Preferred Stock are not entitled to vote on any current proposals.

Pursuant to the terms of the Certificate, holders of the Preferred Stock are entitled to receive, when, as and if declared by the Board of Directors, out of the funds of the Company legally available therefor, cash dividends payable in equal quarterly installments on each of February 1, May 1, August 1, and November 1. The Certificate further provides that, if the Company is in arrears in an aggregate amount equal to at least six quarterly dividends (whether or not consecutive), the number of members of the Company's Board of Directors will be increased by two, effective as of the time of election of such directors, and the holders of Preferred Stock, voting separately as a class, will have the right to vote and elect such two additional directors. This right is accrued to the holders of our Preferred Stock as of August 2, 2010. The Company is currently in arrears in an aggregate amount in excess of six quarterly dividends on the Preferred Stock.

In light of the payment arrearages of the quarterly dividends, the holders of Preferred Stock have a continuing right to elect two directors on the Company's Board of Directors. Coinciding with the closing of a change in control transaction on February 26, 2025, the following persons were elected by the holders of the Series E Preferred Stock to serve on the Board of Directors effective as of April 2, 2025, Dr. Satis Waran Nair Krishnan, and Inigo Angel Laurduraj. They will serve as directors until the earlier the 2026 annual meeting or the time that their successors are duly elected and qualified.

**How Many Votes Do I Have?**

Each share of our Common Stock that you own entitles you to one vote with respect to each of the proposals to be voted on by holders of Common Stock presented in the proxy statement.

**How Do I Vote?**

Whether you plan to attend the annual meeting or not, we urge you to vote by proxy. All shares represented by valid proxies that we receive through this solicitation, and that are not revoked, will be voted in accordance with your instructions on the proxy card or as instructed via the Internet or telephone. You may specify whether your shares should be voted for or withheld for each nominee for director, and whether your shares should be voted for, against or abstain with respect to each of the other proposals. If you properly submit a proxy without giving specific voting instructions, your shares will be voted in accordance with our board of directors' recommendations as noted below. Voting by proxy will not affect your right to attend the annual meeting.

If your shares are registered directly in your name through our transfer agent, Equiniti Trust Company LLC, or you have stock certificates registered in your name, you may vote:

**BY INTERNET OR BY TELEPHONE. FOLLOW THE INSTRUCTIONS ON YOUR NOTICE TO VOTE OVER THE INTERNET. IF YOU RECEIVED A PROXY CARD IN THE MAIL, THE PROXY CARD WILL HAVE INSTRUCTIONS FOR VOTING OVER THE INTERNET OR BY TELEPHONE.**

**BY MAIL. IF YOU RECEIVED ONE OR MORE PROXY CARDS BY MAIL, YOU CAN VOTE BY MAIL BY COMPLETING, SIGNING, DATING AND RETURNING THE ENCLOSED PROXY CARD IN THE ENCLOSED POSTAGE PREPAID ENVELOPE. YOUR PROXY WILL BE VOTED IN ACCORDANCE WITH YOUR INSTRUCTIONS. IF YOU SIGN THE PROXY CARD BUT DO NOT SPECIFY HOW YOU WANT YOUR SHARES VOTED, THEY WILL BE VOTED AS RECOMMENDED BY OUR BOARD OF DIRECTORS.**

**AT THE MEETING. YOU MAY VOTE YOUR SHARES ELECTRONICALLY AT THE VIRTUAL ANNUAL MEETING. YOU WILL NEED THE 16-DIGIT CONTROL NUMBER ON YOUR NOTICE OR PROXY CARD IN ORDER TO VOTE AT THE MEETING. EVEN IF YOU PLAN TO ATTEND THE ANNUAL MEETING VIRTUALLY, WE ENCOURAGE YOU TO VOTE IN ADVANCE SO THAT YOUR VOTE WILL BE COUNTED IN THE EVENT YOU DECIDE NOT TO ATTEND.**

If your shares are held in "street name" by a bank, broker or other nominee, please see the materials you received from your bank, broker or other nominee for voting instructions. To participate and vote during the annual meeting, you will need the 16-digit control number included on your Notice or your voting instruction form. If you do not have your 16-digit control number, you may gain access to and vote at the meeting by logging in to website of your bank, broker or other nominee and selecting the stockholder communications mailbox to access the meeting. Even if you plan to attend the annual meeting virtually, we encourage you to vote in advance so that your vote will be counted in the event you later decide not to attend. Telephone and Internet voting facilities for all stockholders of record will be available 24-hours a day and will close at 11:59 p.m., E.D.T., on June 29, 2025.

**How Does the Board of Directors Recommend that I Vote on the Proposals?**

The Board of Directors recommends that you, as a holder of Common Stock, vote as follows:

● "**FOR**" the re-election of each of Datuk Dr. Doris Wong (to Class 3), Kiu Cu Seng (to Class 2), Kwang Fock Chong (to Class 2), Dr. Satis Waran Nair Krishnan (to Class 1), and Inigo Angel Laurduraj (to Class 1), nominees for directors;

● "**FOR**" the approval of the amendment to our 2018 Equity Incentive Plan to increase the number of shares of Common Stock available for the grant of awards by 4,281,987 shares; and

● "**FOR**" the compensation of our named executive officers and directors, as disclosed in this proxy statement.

In addition, our holders of Common Stock shall consider and act upon such other business and matters as may properly come before the Meeting or any adjournments thereof. The Board of Directors recommends the approval of each of these proposals. If any other matter is properly presented at the annual meeting, your proxy provides that your shares will be voted by the proxy holder listed in the proxy in accordance with the proxy holder's best judgment. At the time this proxy statement was first made available, we knew of no matters that needed to be acted on at the annual meeting, other than those described in this proxy statement.

**May I Change or Revoke My Proxy?**

If you submit a proxy, you may change or revoke it at any time before the annual meeting. You may change or revoke your proxy in any one of the following ways:

● By submitting a new proxy card with a date later than your previously delivered proxy and submitting it as instructed above or by providing written notice of revocation to us before the annual meeting at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 59200, Attention: Kiu Cu Seng, Chief Financial Officer, Executive Director and Secretary;

● By submitting a later proxy by Internet or by telephone as instructed above; or

● By attending the annual meeting and voting at the meeting. Attending the annual meeting will not, in and of itself, change or revoke a previously submitted proxy unless you specifically request it or vote at the annual meeting. Your most current vote, whether by telephone, Internet or proxy card is the one that will be counted.

**What if I Receive More Than One Internet Availability Notice or Proxy Card?**

You may receive more than one Internet Availability Notice or proxy card if you hold shares of our Common Stock in more than one account, which may be in registered form or held in street name. Please vote in the manner described above under "*How Do I Vote?*" for each account to ensure that all of your shares are voted.

**Will My Shares be Voted if I Do Not Vote?**

If your shares are registered in your name or if you have stock certificates, they will not be counted if you do not vote as described above under "*How Do I Vote?*". If your shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your shares as described above, the bank, broker or other nominee that holds your shares has no authority to vote your unvoted shares without receiving instructions from you. Therefore, we encourage you to provide voting instructions to your bank, broker or other nominee. This ensures your shares will be voted on at the annual meeting and in the manner you desire. A "broker non-vote" will occur if your broker, bank or other nominee cannot vote your shares on a particular matter because it has not received instructions from you and does not have discretionary voting authority on that matter or because your broker, bank or other nominee chooses not to vote on a matter for which it does have discretionary voting authority. Therefore, if you hold your shares in street name, it is critical that you cast your vote if you want your vote to be counted.

**What Vote Is Required to Approve Each Proposal and How Are Votes Counted?**

**<u>Proposal 1</u>: Elect Datuk Dr. Doris Wong (to Class 3), Kiu Cu Seng (to Class 2), Kwang Fock Chong (to Class 2), Dr. Satis Waran Nair Krishnan (to Class 1), and Inigo Angel Laurduraj (to Class 1), as Directors:**

The three nominees for director who receive the most votes (also known as a "plurality" of the votes cast) will be elected. You may vote FOR all of the nominees, WITHHOLD your vote from all of the nominees or WITHHOLD your vote from any one of the nominees. Votes that are withheld will not be included in the vote tally for the election of directors. Brokerage firms do not have authority to vote customers' unvoted shares held by the firms in street name for the election of directors. As a result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote.

**<u>Proposal 2</u>: Approval of a Proposed Amendment to our 2018 Equity Incentive Plan to increase the number of shares of Common Stock available for the grant of awards by 4,281,987 shares:**

The affirmative vote of a majority of the votes cast for this proposal is required to approve the amendment to the 2018 Equity Incentive Plan. Abstentions will have no effect on this proposal. Brokerage firms do not have authority to vote customers' unvoted shares held by the firms in street name on this proposal. As a result, any shares not voted by a customer will be treated as a broker non- vote. Such broker non-votes will have no effect on the results of this vote.

**<u>Proposal 3</u>: Approve an Advisory Vote on the Compensation of our Named Executive Officers and Directors:**

The affirmative vote of a majority of the votes cast for this proposal at the annual meeting is required to approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement. Abstentions will have no effect on this proposal. Brokerage firms do not have authority to vote customers' unvoted shares held by the firms in street name on this proposal. As a result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote.

**Is Voting Confidential?**

We will keep all of the proxies, ballots and voting tabulations private. We only let our Inspector of Election, a representative of Broadridge Financial Solutions, Inc., examine these documents. Management will not know how you voted on a specific proposal unless it is necessary to meet legal requirements. Broadridge Financial Solutions, Inc., however, will forward to management any written comments you make, on the proxy card or elsewhere.

**Where Can I Find the Voting Results of the Annual Meeting?**

The preliminary voting results will be announced at the annual meeting, and we will publish preliminary, or final, results, if available, in a Current Report on Form 8-K within four business days of the annual meeting. If final results are unavailable at the time we file the Form 8-K, then we will file an amended report on Form 8-K to disclose the final voting results within four business days after the final voting results are known.

**What Are the Costs of Soliciting these Proxies?**

We will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies in person or by telephone, fax or email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority to execute proxies. We will then reimburse them for their expenses.

We have engaged Laurel Hill Advisory Group, LLC, to act as our proxy solicitor in connection with the proposals to be acted upon at our annual meeting. Pursuant to our agreement, Laurel Hill Advisory Group, LLC will, among other things, provide advice regarding proxy solicitation issues and solicit proxies from our stockholders on our behalf in connection with the annual meeting. For these services, we will pay a fee of approximately $20,000 plus expenses.

**What Constitutes a Quorum for the Annual Meeting?**

The presence, at the meeting or by proxy, of the holders of a majority of the voting power of all outstanding shares of our Common Stock entitled to vote at the annual meeting is necessary to constitute a quorum at the annual meeting. Votes of stockholders of record who are present at the annual meeting or by proxy, abstentions, and broker non-votes are counted for purposes of determining whether a quorum exists. Broker non-votes will be counted for purposes of determining whether a quorum exists with respect to all of the Proposals.

**Attending the Annual Meeting**

This year, the annual meeting will be held in a virtual meeting format only. To attend the annual meeting, go to www.proxyvote.com shortly before the meeting time, and follow the instructions. You need not attend the annual meeting in order to vote.

**Householding of Annual Disclosure Documents**

Some brokers or other nominee record holders may be sending you a single set of our proxy materials if multiple of our stockholders live in your household. This practice, which has been approved by the SEC, is called "householding." Once you receive notice from your broker or other nominee record holder that it will be "householding" our proxy materials, the practice will continue until you are otherwise notified or until you notify them that you no longer want to participate in the practice. Stockholders who participate in householding will continue to have access to and utilize separate proxy voting instructions.

We will promptly deliver a separate copy of our Internet Availability Notice. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639, or (3) send an email to <u>sendmaterial@proxyvote.com</u>. If you send an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

**Electronic Delivery of Company Stockholder Communications**

Most stockholders can elect to view or receive copies of future proxy materials over the Internet instead of receiving paper copies in the mail. You can choose this option and save us the cost of producing and mailing these documents by:

● following the instructions provided on your Internet Availability Notice or proxy card;

● following the instructions provided when you vote over the Internet; or

● going to *www.proxyvote.com* and following the instructions provided.

**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The following table sets forth certain information with respect to the beneficial ownership of our Common Stock and our preferred stock (the "Preferred Stock") as of April 24, 2025 for (a) each of our named executive officers, (b) each of our directors and director nominees, (c) all of our current directors and executive officers as a group, and (d) each stockholder known by us to own beneficially more than 5% of our Common Stock or Preferred Stock, relying solely upon the amounts and percentages disclosed in their public filings.

Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. We deem shares of Common Stock that may be acquired by an individual or group within 60 days of April 24, 2025 pursuant to the exercise of options or warrants to be outstanding for the purpose of computing the percentage ownership of an individual or group but do not deem them to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of stock shown to be beneficially owned by them based on information provided to us by these stockholders.

The percentage of ownership of Common Stock is based on 356,357,531 shares of Common Stock outstanding as of April 24, 2025. The percentage of ownership of Preferred Stock is based on 135,537 shares of Preferred Stock outstanding as of April 24, 2025.

The address for each of the directors, director nominees and named executive officers is c/o Cyclacel Pharmaceuticals, Inc., Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 59200. Addresses of other beneficial owners are noted in the table.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name of Beneficial Owners <sup>(1)</sup>** | **Number of Shares of Common Stock Beneficially Owned** | **Percentage of**<br> **Outstanding**<br> **Shares of**<br> **Common**<br> **Stock<sup>(2)</sup>** | **Number of Shares of Preferred Stock Beneficially Owned <sup>(2)</sup>** | **Percentage of Preferred Stock Owned <sup>(2)</sup>** |
| David Lazar | 39021180 | 10.95% | – |  |
| Armistice Capital Master Fund Ltd.<sup>(3)</sup> | 24844725 | 6.97% | – |  |
| Ho Kee Wee<sup>(4)</sup> | 27500000 | 7.72% | – |  |
| Tan Kok Hui<sup>(5)</sup> | 27500000 | 7.72% | – |  |
| Suria Sukses Engineering Sdn. Bhd.<sup>(6)</sup> | 27500000 | 7.72% | – |  |
| Ho Jien Shiung<sup>(7)</sup> | 27500000 | 7.72% | – |  |
| Datuk Dr. Doris Wong Sing Ee<sup>(8)</sup> | 194628820 | 54.61% | – |  |
| Kiu Cu Seng |  |  | – |  |
| Kwang Fock Chong |  |  | – |  |
| Dr. Satis Waran Nair Krishnan |  |  | – |  |
| Inigo Angel Laurduraj |  |  | – |  |

---

__________________

\* Represents beneficial ownership of less than one percent of our outstanding shares of Common Stock.

(1) Unless
 otherwise indicated, the address of each beneficial owner listed below is c/o Cyclacel Pharmaceuticals, Inc., Cyclacel Pharmaceuticals,
 Inc., Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia.

(2) Assumes
 the sale of all shares of Common Stock being offered pursuant to this prospectus.

(3) Armistice
 Capital Master Fund Ltd. ("Armistice") and the Company entered into that certain Warrant Exchange Agreement dated January
 2, 2025 ("Warrant Exchange Agreement"), pursuant to which they agreed to exchange certain Exchanged Warrants (as defined
 in the Warrant Exchange Agreement) previously acquired by Armistice for 24,844,725 shares of common stock and cash consideration.
 The address for Armistice is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, New York 10022. Armistice is a
 Cayman Islands exempted company operating as a hedge fund focused primarily on the health care and consumer sectors. We have been
 advised that Steven Boyd has the power to vote or direct the vote and power to dispose or to direct the disposition of all securities
 owned directly by Armistice. We have been advised that Armistice is a member of the Financial Industry Regulatory Authority ("FINRA"),
 or an independent broker-dealer, and that neither Armistice nor any of its affiliates is an affiliate or an associated person of
 any FINRA member or independent broker-dealer.

(4) Based
 solely on the Securities Purchase Agreement dated March 21, 2025 between the Company and Ho Kee Wee, as filed within the Company's
 Current Report on Form 8-K filed with the SEC on March 24, 2025 for the purchase of 250,000 shares of Series E Preferred Stock that
 are convertible into 27,500,000 shares of common stock.

(5) Based
 solely on the Securities Purchase Agreement dated March 21, 2025 between the Company and Tan Kok Hui, as filed within the Company's
 Current Report on Form 8-K filed with the SEC on March 24, 2025 for the purchase of 250,000 shares of Series E Preferred Stock that
 are convertible into 27,500,000 shares of common stock.

(6) Based
 solely on the Securities Purchase Agreement dated March 21, 2025 between the Company and Suria Sukses Engineering Sdn. Bhd. ("Suria"),
 as filed within the Company's Current Report on Form 8-K filed with the SEC on March 24, 2025 for the purchase of 250,000 shares
 of Series E Preferred Stock that are convertible into 27,500,000 shares of common stock. The address for Suria is 26-13A Stellar
 Suites, Jalan Puteri 4/7, Bandar Puteri, 47100 Puchong, Selangor, Malaysia. Suria is in the business of production of the Giant HVLS
 fan in Malaysia sold under the brand Suria Giant Fan. We have been advised that Chen Choon Seng has power to vote or direct the vote
 and power to dispose or to direct the disposition of all securities owned directly by Suria.

(7) Based
 solely on the Securities Purchase Agreement dated March 21, 2025 between the Company and Ho Jien Shiung, as filed within the Company's
 Current Report on Form 8-K filed with the SEC on March 24, 2025 for the purchase of 250,000 shares of Series E Preferred Stock that
 are convertible into 27,500,000 shares of common stock.

(8) The
 Company's Chief Executive Officer, Datuk Dr. Doris Wong Sing Ee is the Majority Stockholder referred to herein who controls
 the management and affairs of the Company, and currently can control matters requiring the approval by the Company's stockholders,
 including the election of directors, any merger, consolidation or sale of all or substantially all of its assets, and any other significant
 corporate transaction.

**MANAGEMENT AND CORPORATE GOVERNANCE**

**The Board of Directors**

Our charter provides that our business is to be managed by or under the direction of our Board of Directors. Our Board of Directors is divided into three classes for purposes of election. One class is elected at each annual meeting of stockholders to serve for a three-year term. Our Board of Directors currently consists of three classes, as set forth below. We also have two directors who are elected by holders of our Series E Preferred Stock (the "Preferred Stock").

Effective as of February 26, 2025, the Board of Directors appointed Datuk Dr. Doris Wong Sing Ee, as Chief Executive Officer and, in such role, she will serve as the Company's principal executive officer. Datuk Dr. Doris Wong Sing Ee was also elected to the Board of Directors as an Executive Director of the Company as of that date.

Effective as of February 26, 2025, the Board appointed Kiu Cu Seng, as Chief Financial Officer and, in such role, he will serve as the Company's principal financial office and as Executive Director and Secretary. The Company's Board of Directors also appointed Mr. Kiu as Executive Director and Secretary.

Effective as of April 2, 2025, the following persons were elected by the holders of the Series E Preferred Stock to serve on the Board of Directors, Dr. Satis Waran Nair Krishnan and Inigo Angel Laurduraj.

Set forth below are the names of the persons who are nominated as directors for election at the annual meeting as well as the directors whose terms do not expire this year, their ages, their offices in the Company, if any, their principal occupations or employment for at least the past five years, the length of their tenure as directors and the names of other public companies in which such persons hold or have held directorships during the past five years. Additionally, information about the specific experience, qualifications, attributes or skills that led to our Board of Directors' conclusion at the time of filing this proxy statement that each person listed below should serve as a director is set forth below:

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position** |
| Datuk Dr. Doris Wong | 43 | Chief Executive Officer and Executive Director |
| Kiu Cu Seng | 36 | Chief Financial Officer, Executive Director and Secretary |
| Kwang Fock Chong | 46 | Independent Director |
| Dr. Satis Waran Nair Krishnan | 39 | Independent Director |
| Inigo Angel Laurduraj | 40 | Independent Director |

---

**Board Diversity Matrix (as of April 24, 2025)**

This table provides information on the diversity of our current Board of Directors:

---

| | | |
|:---|:---|:---|
| **Total Number of Directors** | 5 |  |
|  | **Female** | **Male** |
| **Part I: Gender Identity** |  |  |
| Directors | 2 | 3 |
| **Part II: Demographic Background** |  |  |
| African American or Black | 0 | 0 |
| Hispanic or Latinx | 0 | 0 |
| Asian | 2 | 3 |
| White | 0 | 0 |

---

 ****

 ****

***Datuk Dr. Doris Wong.*** Datuk Dr. Wong brings more than 20 years of management experience to her roles as Chief Executive Officer and Executive Director of the Company across various industries ranging from oil and gas, property development, solar, engineering, advertising, food and beverage, raw materials and more. She specializes in business development, strategic consultancy and corporate advisory in mergers and acquisition and joint venture across Malaysia, Singapore, China, Japan, Thailand and Indonesia. Since October 2020, Datuk Dr. Wong has been serving as an Executive Director of Metronic Global Bhd, an investment holding company, where she has been optimizing financial operations, establishing business goals, advising the board of directors on organizational activities and executing special business projects. She has also been involved in various investment opportunities in business diversification, generating new revenue and increasing shareholders' wealth.

Datuk Dr. Wong has also been serving as the Executive Director of BSL Corporation Berhad (KLSE: BSLCORP) since May 2024, a public listed company with its business segments constituting stamping and manufacturing of precision metal parts and fabrication of tools and dies, printed circuit boards (PCB) assembly of all types of electronics and electrical components, devices and systems, fabrication and forging of base metal components for consumer products. Datuk Dr. Wong served as an independent director and member of the audit committee and the compensation committee of Energem Corp from its initial public offering on November 16, 2021 until her appointment as Executive Director on January 27, 2023. Following Energem Corp's completion of a series of transactions that resulted in its business combination with Graphjet Technology Sdn. Bhd. (Nasdaq: GTI), a Malaysian private limited company ("Graphjet") on March 14, 2024, Datuk Dr. Doris Wong Sing Ee served as a director of Graphjet until January 6, 2025.

Since February 2017, Datuk Dr. Wong has been a non-independent non-executive director at Trive Property Group Bhd (0118.KL). Previously, from January 2019 to September 2020, Datuk Dr. Wong served as Chief Corporate Officer in Metronic Engineering Sdn. Bhd. (0043.KL) where she oversaw HR operations, set objectives for the HR team and helped shape the brand strategy of the company. Datuk Dr. Wong served as General Manager from 2015 to 2016 in Dai-Ichi Kikaku Sdn. Bhd. where she was overseeing and handling business development, client strategy and direction, creative, production, media planning, procurement and research. From 2012 to 2015, Datuk Dr. Wong served as Strategic Business Consultant for JLPW Law Firm where she handled mergers and acquisitions and joint venture deals internationally for various industries and from 2002 to 2012, Datuk Dr. Wong started her career as a Managing Director at Niagamatic Sdn. Bhd., where she controlled all business operations to give strategic guidance and directions to the board and staff to ensure the company achieved its financial vision, mission and long-term goals.

***Kiu Cu Seng.*** Mr. Kiu brings significant accounting and audit experience involving publicly listed companies during his years working with accounting standards. Mr. Kiu served as Energem Corp's Chief Financial Officer from August 12, 2021 through its completion of a series of transactions that resulted in its business combination with Graphjet on March 14, 2024. Since March 2021, Mr. Kiu has served as Group Accountant for BCM Alliance Bhd, Sanichi Technology Bhd. and Trive Property Group Bhd. His responsibility is on group consolidation issues. From June 2019 to February 2021, Mr. Kiu served as Manager in SBY & Partners PLT (formerly known as Siew Boon Yeong & Associates) an established professional accounting organization providing a comprehensive range of services ranging from audit and assurance, taxation and accounting where he specialized in auditing matters.

From June 2017 to February 2019, Mr. Kiu served as a Senior Auditor with Siew Boon Yeong & Associates. Prior to that, from December 2016 to June 2017, Mr. Kiu served as a semi-senior auditor at the corporate compliance firm, Z. AMIN and he started his career in 2013 until December 2016 with YTS & Associate. Mr. Kiu graduated from Infrastructure University Kuala Lumpur in the year 2013 with a bachelor's degree (with Honors) in Accounting and from Kuala Lumpur Infrastructure University College with a Diploma in Accounting in 2009.

***Kwang Fock Chong***. Mr. Chong is a Chartered Accountant in Malaysia, and brings nearly 20 years of working experience to the Company. He served as an Independent Director, Chair of the Audit Committee and member of the Compensation Committee of Energem Corp since its initial public offering on November 16, 2021 until its business combination with Graphjet on March 14, 2024. His experience includes auditing of public listed companies, multinationals and private limited companies in various industries. Other than conducting statutory audit in Malaysia, he also performed audit for companies based in China and the AIPAC region. He was also involved in Reporting Accountants' engagement on initial public offering exercise, due diligence, reviewing financial forecast and projections.

Mr. Chong serves as Auditor and Partner of KHLC PLT where his main responsibility is reviewer and signing partner since October 2020. From July 2014 to September 2020, Mr. Chong served as Auditor and Partner of SBY Partners PLT that provides audit and assurance services where his main responsibilities were to serve as reviewing and signing partner. Mr. Chong received his Diploma in 2002 from Tunku Abdul Rahman College in Financial Accounting and achieved his Association of Chartered Certified Accountants certification in 2005.

***Dr. Satis Waran Nair Krishnan.*** Dr. Krishnan is a Medical Doctor at Centric Health in Drogheda, County Louth, Ireland. Dr. Krishnan is a highly experienced practitioner originally from Malaysia. Dr. Krishnan joined Centric Health in Ireland September 2023. Prior to that, from 2010 to August 2023, Dr. Krishnan was a Doctor in the public health field for the Ministry of Health Malaysia, With a decade of practice in Malaysia and training in Dermatology from the Association of Family Physicians of Malaysia (AFPM) and the Institute of Dermatology in Bangkok, Thailand, Dr. Krishnan brings a wealth of expertise to our team. Dr. Nair is proficient in English, Russian and Ukrainian, he is dedicated to providing patient-centered care and promoting overall well-being. Dr. Krishnan received his medical degree in 2010 and a Professional Diploma of General Dermatology in 2023.

 ****

***Inigo Angel Laurduraj.*** Ms. Laurduraj brings extensive audit and accounting services to the Company over her 20 years in that industry. Ms. Laurduraj served as a Senior Accounting Manager at IOI Oleochemicals Sdn. Bhd., an edible oil refining and oleochemicals company for 11 years from 2007 through 2018. Prior to that, she served from 2005 through 2005 as an Auditor for Moore Stephens (now Moore Global), a global firm operating in 114 countries specializing in accounting and finance services, audit and assurance, fund services, private client services, corporate services, and tax services. Ms. Laurduraj earned an Association of Chartered Certified Accountants (ACCA) in 2015 and a Bachelor of Arts in Accounting in 2014.

 ****

**Director Independence**

Our Board of Directors has reviewed the materiality of any relationship that each of our directors has with the Company, either directly or indirectly. Based upon this review, our Board of Directors has determined that each of the following directors is an "independent director" as such term is defined by rules of The Nasdaq Stock Market, Inc., or Nasdaq:

● Kwang Fock Chong,

● Dr. Satis Waran Nair Krishnan, and

● Inigo Angel Laurduraj

In connection with Ms. Laurduraj and Dr. Krishnan's appointment, as well as the Board of Directors appointment of Mr. Kwang Fock Chong as independent director on February 26, 2025, on April 2, 2025, the Board of Directors also approved the following committee appointments after a thorough review of all of the candidates' backgrounds, relevant experience and professional and personal reputations:

**●**  **<u>Audit Committee</u> — Kwang Fock Chong (Chair); Inigo Angel Laurduraj; and Dr. Satis Waran Nair Krishnan** 

**●**  **<u>Compensation and Organization Committee</u> — Inigo Angel Laurduraj (Chair); Kwang Fock Chong; and Dr. Satis Waran Nair Krishnan** 

**●**  **<u>Nominating and Governance Committee</u> — Dr. Satis Waran Nair Krishnan (Chair), Kwang Fock Chong and Inigo Angel Laurduraj** 

The Board also determined that each of Kwang Fock Chong, Inigo Angel Laurduraj, and Dr. Satis Waran Nair Krishnan also satisfy the additional requirements of financial literacy and audit committee independence for audit committee service under the applicable rules and regulations of the SEC and the listing standards of Nasdaq.

**Committees of the Board of Directors and Meetings**

*Meeting Attendance*. During fiscal 2024, there were 31 meetings of our Board of Directors, and the Compensation and Organization Development Committee, the Audit Committee, the Nominating and Corporate Governance Committee and the Science and Technology Committee met collectively a total of 9 times. No director attended fewer than 80% of the total number of meetings of the Board of Directors or of the committees of the Board of Directors on which they served during fiscal 2024. We have adopted a policy encouraging our directors to attend annual meetings of stockholders. All of our then directors attended our annual stockholders' meeting held on June 21, 2024. Each of the committees of the Board of Directors is described below.

*Audit Committee*. Our Audit Committee met 5 times during fiscal 2024. The Audit Committee during such period had four members: Karin L. Walker (Chair), Dr. Christopher Henney, Dr. Samuel L. Barker and Dr. Robert J. Spiegel. Karin L. Walker was appointed as Chairman of the Audit Committee on February 18, 2021. All members of the Audit Committee satisfy the current independence standards promulgated by Nasdaq and the SEC, as such standards apply specifically to members of audit committees. The Board of Directors has determined that Karin L. Walker is an "audit committee financial expert," as the SEC has defined that term in Item 407 of Regulation S-K.

Our Audit Committee's role and responsibilities are set forth in the Audit Committee's written charter and include the authority to retain and terminate the services of our independent registered public accounting firm. In addition, the Audit Committee reviews annual financial statements, considers matters relating to accounting policy and internal controls and reviews the scope of annual audits. For additional information, please see the report of the Audit Committee set forth elsewhere in this proxy statement. A copy of the Audit Committee's written charter is publicly available on our website at *www.cyclacel.com*.

*Compensation and Organization Development Committee*. Our Compensation and Organization Development Committee met once during fiscal 2024. The Compensation and Organization Development Committee is composed entirely of directors who are not our current or former employees, all of whom qualify as independent under the definition promulgated by Nasdaq and the SEC. The Compensation and Organization Development Committee currently has three members: Dr. Samuel L. Barker (Chairman), Dr. Christopher S. Henney and Dr. Kenneth M. Ferguson. Our Compensation and Organization Development Committee's role and responsibilities are set forth in its written charter and include reviewing, approving and making recommendations regarding our compensation policies, practices and procedures to ensure that legal and fiduciary responsibilities of the Board of Directors are carried out and that such policies, practices and procedures contribute to our success. The Compensation and Organization Development Committee also administers our 2020 Inducement Equity Incentive Plan, our 2018 Equity Incentive Plan, our 2015 Equity Incentive Plan and our Amended and Restated 2006 Equity Incentive Plan, as amended. Our Compensation and Organization Development Committee is responsible for the determination of the compensation of our chief executive officer, and shall conduct its decision making process with respect to that issue without the chief executive officer present. A copy of the Compensation and Organization Development Committee's written charter is publicly available on our website at www.cyclacel.com.

*Nominating and Corporate Governance Committee*. Our Nominating and Corporate Governance Committee met once during fiscal 2024. The Nominating and Corporate Governance Committee consists of Dr. Christopher S. Henney (Chairman), Karin L. Walker and Dr. Robert J. Spiegel, all of whom qualify as independent under the definition promulgated by Nasdaq and the SEC. Dr. Brian Schwartz resigned from the Nominating and Corporate Governance Committee when appointed interim Chief Medical Officer on January 25, 2024. The functions of the Nominating and Corporate Governance Committee are set forth in the Nominating and Corporate Governance Committee's charter and include evaluating and making recommendations to the full Board of Directors as to the size and composition of the Board of Directors and its committees, evaluating and making recommendations as to potential candidates, and evaluating the performance of the Board of Directors. Generally, our Nominating and Corporate Governance Committee considers candidates recommended by stockholders as well as from other sources such as other directors or officers, third party search firms or other appropriate sources. Once identified, the Nominating and Corporate Governance Committee will evaluate a candidate's qualifications in accordance with its guiding principles as set forth in the Nominating and Corporate Governance Committee's written charter.

Additionally, the Nominating Committee will consider issues of diversity among its members in identifying and considering nominees for director, and strive where appropriate to achieve a diverse balance of backgrounds, perspectives, professional experience, age, gender, ethnicity and country of citizenship on our board of directors and its committees.

If a stockholder wishes to nominate a candidate for director who is not to be included in our proxy statement, it must follow the procedures described in our By-Laws and in "*Stockholder Proposals and Nominations for Director*" at the end of this proxy statement.

In addition, under our current corporate governance policies, the Nominating and Corporate Governance Committee may consider candidates recommended by stockholders as well as from other sources, such as other directors or officers, third party search firms or other appropriate sources. For all potential candidates, the Nominating and Corporate Governance Committee may consider all factors it deems relevant, such as a candidate's personal integrity and sound judgment, business and professional skills and experience, independence, knowledge of the industry in which we operate, possible conflicts of interest, diversity, the extent to which the candidate would fill a present need on the Board of Directors and concern for the long-term interests of the stockholders. In general, persons recommended by stockholders will be considered on the same basis as candidates from other sources. A copy of the Nominating and Corporate Governance Committee's written charter is publicly available on our website at *www.cyclacel.com*.

 

*Science and Technology Committee*. The Science and Technology Committee, which met twice during fiscal 2024, consists of Dr. Robert J. Spiegel (Chairman), Dr. Samuel L. Barker, Dr. Kenneth M. Ferguson and Dr. Brian Schwartz.

The responsibilities of the Science and Technology Committee are set forth in the Science and Technology Committee's charter and include providing oversight on behalf of the Board of Directors of our overall strategic direction and investment in research and development ("R&D") and technological and scientific initiatives. The Science and Technology Committee also assists the Board of Directors and our management in evaluating the risks and potential commercial value of technical profiles regarding our R&D programs and technology, as they might impact our business performance, growth and competitive position.

**Board Leadership Structure**

At present, Datuk Dr. Doris Wong serves as the Chairman of our Board of Directors, Chief Executive Officer and Executive Director. We recognize that different board leadership structures may be appropriate for companies in different situations. We will continue to re-examine our corporate governance policies and leadership structures on an ongoing basis to ensure that they continue to meet the Company's needs.

**Role in Risk Oversight**

Management is responsible for managing the risks that we face. The Board of Directors is responsible for overseeing management's approach to risk management that is designed to support the achievement of organizational objectives, including strategic objectives and risks associated with our clinical trials, to improve long-term organizational performance and enhance stockholder value. The involvement of the full Board of Directors in reviewing our strategic objectives and plans, including with respect to our clinical trials, is a key part of the Board of Directors' assessment of management's approach and tolerance to risk. A fundamental part of risk management is not only understanding the risks a company faces and what steps management is taking to manage those risks, but also understanding what level of risk is appropriate for us. In setting our business strategy, our Board of Directors assesses the various risks being mitigated by management and determines what constitutes an appropriate level of risk for us.

While the Board of Directors has ultimate oversight responsibility for overseeing management's risk management process, various committees of the Board of Directors assist it in fulfilling that responsibility. Notably, the Audit Committee assists the Board of Directors in its oversight of risk management in the areas of financial reporting, internal controls and compliance with legal and regulatory requirements, the Nominating and Corporate Governance Committee reviews legal and regulatory compliance risks and the Compensation and Organization Development Committee assists the Board of Directors in its oversight of the evaluation and management of risks related to our compensation policies and practices.

**Policy Prohibiting Hedging**

Our Insider Trading Policy provides that no employee, officer or director may acquire, sell or trade in any interest or position relating to the future price of Company securities, such as a put option, a call option or a short sale (including a short sale "against the box"), or engage in hedging transactions (including "cashless collars").

**Stockholder Communications to the Board of Directors**

Generally, stockholders who have questions or concerns should contact our Investor Relations department at (908) 517-7330 or e-mail at *ir@cyclacel.com*. However, stockholders wishing to submit written communications directly to the Board of Directors should send their communications to our Secretary, Kiu Cu Seng, Cyclacel Pharmaceuticals, Inc., Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 59200. All stockholder communications will be considered by the independent members of our Board of Directors. Items that are unrelated to the duties and responsibilities of the Board may be excluded, such as:

● junk mail and mass mailings;

● resumes and other forms of job inquiries;

● surveys; and

● solicitations or advertisements.

In addition, any material that is unduly hostile, threatening, or illegal in nature may be excluded, provided that any communication that is filtered out will be made available to any independent director upon request.

**EXECUTIVE AND DIRECTOR COMPENSATION**

**Summary Compensation Table**

The following table shows the compensation paid or accrued during the last two fiscal years ended December 31, 2023 and 2024 to (1) our Chief Executive Officer and Executive Director, (2) our Executive Vice President, Finance, Chief Financial Officer and Chief Operating Officer, and (3) our former Senior Vice President and Chief Medical Officer.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name and Principal Position** | **Year** | **Salary <br>($)** | **Bonus <br>($)** | **Option Awards**<br> **($)<sup>(1)</sup>** | **All Other Compensation**<br> **($)<sup>(2)</sup>** | **Total <br>($)** |
| Spiro Rombotis, President and Chief Executive Officer | 2024 | 560131 | &nbsp;&nbsp;&nbsp;&nbsp;0 | 0 | 24869 | 585000 |
|  | 2023 | 560131 | 0 | 48581 | 52337 | 661049 |
| Paul McBarron, Executive Vice President, Finance, Chief Financial Officer, Chief Operating Officer, Secretary<sup>(3)</sup> | 2024 | 312615 | 0 | 0 | 21008 | 333623 |
|  | 2023 | 304214 | 0 | 31003 | 17398 | 352615 |
| Mark Kirschbaum, MD, Former Senior Vice President and Chief Medical Officer<sup>(4)</sup> | 2024 | 30365 | 0 | 0 | 0 | 30365 |
|  | 2023 | 396760 | 0 | 31003 | 52855 | 480618 |

---

(1) These
 amounts represent the aggregate grant date fair value for option awards computed in accordance with FASB ASC Topic 718. A discussion
 of the assumptions used in determining grant date fair value may be found in our Financial Statements included in our Annual Report
 on Form 10-K for the year ended December 31, 2024. Options were granted during the year ended December 31, 2023 to Spiro Rombotis,
 Paul McBarron, and Mark Kirschbaum in the amounts of 7,333 shares, 4,680 shares, and 4,680 shares, respectively.

(2) Consists
 of the following for all executive officers: Payments for private medical and health insurance, life insurance and permanent health
 insurance; and matching contributions made under the Company's U.S. 401(k) Plan and U.K. Group Personal Pension Plan.

(3) Mr.
 McBarron's compensation was translated from British pound sterling to the U.S. dollar using the exchange rates of 1.27795 as
 of December 31, 2024 and 1.24361 as of December 31, 2023.

(4) Dr.
 Kirschbaum was terminated as Chief Medical Officer on January 25, 2024.

**Narrative Disclosure to Summary Compensation Table**

The Compensation and Organization Development Committee of our Board of Directors makes decisions regarding the compensation of our Chief Executive Officer and Executive Director. The Compensation and Organization Development Committee is composed entirely of independent directors and meets in executive sessions to discuss and formulate its recommendations for the Chief Executive Officer's base salary and bonus. The Compensation and Organization Development Committee does not rely solely on any predetermined formula or a limited set of criteria in evaluating the Chief Executive Officer's performance for the year but does consider the achievement of preset goals as part of its deliberations.

The evaluation is based on the Chief Executive Officer's success in achieving his performance goals, which include financial, strategic and leadership objectives. The Chief Executive Officer also provides the Compensation and Organization Development Committee with a self-review of his performance as part of the Company's review process. The Compensation and Organization Development Committee also approves the annual compensation (including base salary, bonus, and stock-based compensation) for our other named executive officers based on:

● the executive's scope of responsibilities;

● an informed market assessment of competitive practices for similar roles within peer group companies;

● evaluations of performance for the year, as assessed by the Chief Executive Officer, supported by the Company's performance review process and the executive's self-assessment; and

● recommendations by our Chief Executive Officer for each named executive officer with respect to base salary, cash bonus, and stock-based compensation.

The Compensation and Organization Development Committee is authorized to engage and retain independent consultants and other experts to assist in fulfilling its responsibilities, and the Committee engages periodically an external consultant to provide independent verification of market position and ensure the appropriateness of executive compensation.

During the most recent year ended December 31, 2024, the Board of Directors and the Compensation and Organization Development Committee reviewed the annual compensation for our executive officers and made no changes.

We did not grant stock options or restricted stock units to Spiro Rombotis and Paul McBarron during the year ended December 31, 2024.

*Spiro Rombotis, President and Chief Executive Officer.* On April 28, 2023, we entered into a two-year employment agreement with Mr. Spiro Rombotis, effective January 1, 2023 and which terminated on January 6, 2025 coinciding with his resignation. Mr. Rombotis was paid an annual base salary of $560,131 for the year ending December 31, 2024 and $560,131, for the year ending December 31, 2023, respectively. In addition, Mr. Rombotis agreed to certain confidentiality and assignment of inventions obligations and will be subject to certain non-competition obligations for a period of one year following termination of his employment.

*Paul McBarron Executive Vice President, Finance, Chief Financial Officer, Chief Operating Officer, Secretary.* On April 28, 2023, we entered into a two-year employment agreement with Mr. McBarron, effective January 1, 2023 and which terminated on January 6, 2025 coinciding with his resignation. Mr. McBarron was paid an annual base salary of £244,622, or $312,615 for the year ending December 31, 2024 and £244,622, or $304,214, for the year ending December 31, 2023, respectively. In addition, Mr. McBarron agreed to certain confidentiality and assignment of inventions obligations and will be subject to certain non-competition obligations for a period of one year following termination of his employment.

*Mark Kirschbaum, Former Senior Vice President and Chief Medical Officer*. On October 17, 2020, we entered into an employment agreement with Dr. Mark Kirschbaum, effective October 23, 2020. We terminated Dr. Kirschbaum's employment on January 25, 2024. Prior to his termination, Dr. Kirschbaum' annual base salary was $396,760. Dr. Kirschbaum was paid an annual base salary of $30,365 for the partial year ending December 31, 2024 and $396,760 for the year ending December 31, 2023. Dr. Kirschbaum also agreed to certain confidentiality and assignment of inventions obligations and will be subject to certain non-competition obligations for a period of one year following termination of his employment.

**EQUITY COMPENSATION PLAN INFORMATION**

**Outstanding Equity Awards at 2024 Fiscal Year-End**

The following table shows grants of stock options outstanding on the last day of the fiscal year ended December 31, 2024, to each of the executive officers named in the Summary Compensation Table in the section titled "EXECUTIVE AND DIRECTOR COMPENSATION" above.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Number of Securities Underlying Options Exercisable** |  | **Number of Securities Underlying Options Unexercisable** | **Option Exercise Price<sup>(1)</sup>**<br> **($)** | **Option Expiration Date** |
| Spiro Rombotis | 121 | (2) |  | 2120.40 | 12/07/2025 |
|  | 104 | (3) |  | 522.00 | 12/29/2027 |
|  | 95 | (3) |  | 468.00 | 02/22/2028 |
|  | 1693 | (4) |  | 213.00 | 01/04/2029 |
|  | 11666 | (5) |  | 64.80 | 12/11/2030 |
|  | 12666 | (6) |  | 51.75 | 12/13/2031 |
|  | 0 | (7) | 7333 | 8.70 | 06/27/2033 |
| Paul McBarron | 72 | (2) |  | 2120.40 | 12/07/2025 |
|  | 86 | (3) |  | 522.00 | 12/29/2027 |
|  | 79 | (3) |  | 468.00 | 02/22/2028 |
|  | 900 | (4) |  | 213.00 | 01/04/2029 |
|  | 7999 | (5) |  | 64.80 | 12/11/2030 |
|  | 6666 | (6) |  | 51.75 | 12/13/2031 |
|  | 0 | (7) | 4680 | 8.70 | 06/27/2033 |

---

(1) The
 option exercise price is the closing price of our Common Stock on The Nasdaq Capital Market on the date the option was granted.

(2) These
 options were granted on December 7, 2015, and vest ratably on a monthly basis over 36 months.

(3) Certain
 performance criteria were deemed to have been met in 2018 and 2019, and as such, performance-based options granted in 2017 and 2018
 vested.

(4) These
 options were granted on January 4, 2019 and included part of the 2018 bonus award, and vest ratably on a monthly basis over 36 months.

(5) These
 options were granted on December 11, 2020, and vest ratably on a monthly basis over 36 months.

(6) These
 options were granted on December 13, 2021, and vest ratably on a monthly basis over 36 months.

(7) These
 options were granted on June 27, 2023, are performance based vesting, and will lapse May 7, 2025 due to performance criteria not
 being met.

**Potential Payments Upon Termination or Change-in-Control**

We have entered into agreements that require us to make payments and/or provide benefits to certain of our executive officers in the event of a termination of employment or change-in-control. Our 2006 Equity Incentive Plan, or 2006 Plan, our 2015 Equity Incentive Plan, or 2015 Plan, our 2018 Equity Incentive Plan, or 2018 Plan, and our 2020 Inducement Equity Incentive Plan, or 2020 Plan (and collectively with the 2006 Plan, 2015 Plan, and 2018 Plan the "Plans") provide for payments to named executive officers in connection with a termination or a change-in-control of the Company. All of such agreements that require us to make payments and/or provide benefits to certain of our executive officers in the event of a termination of employment or change-in-control have terminated.

**Director Compensation**

The following table shows the total compensation paid or accrued during the fiscal year ended December 31, 2024 to each of our non-employee directors. Directors who are employed by us are not compensated for their service on our Board of Directors.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Fees Earned or<br> Paid in Cash<br> ($)** | **Option Awards**<br> **($)<sup>(1)(2)</sup>**  | **Stock Awards**<br> **($)<sup>(1)(3)</sup>**  | **Total<br> ($)** |
| Christopher S. Henney, Ph.D. D.Sc. | $84058 |  |  | $84058 |
| Robert J. Spiegel, M.D. | $84500 | $— | $— | $84500 |
| Samuel L. Barker, Ph.D. | $85058 | $— | $— | $85058 |
| Kenneth M. Ferguson, Ph.D. | $56637 | $— | $— | $56637 |
| Brian Schwartz, M.D. | $49274 | $22130 | $28500 | $99904 |
| Karin L. Walker | $64000 | $— | $— | $64000 |

---

(1) These
 amounts represent the aggregate grant date fair value of options and restricted stock units granted to each director during the year
 ended December 31, 2024 computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant
 date fair value may be found in Note 11 to our financial statements included on our Form 10-K for the fiscal year ended December
 31, 2024.

(2) The
 fair value of the options granted on January 29, 2024 was $1.77 per share. A total of 12,500 stock options were granted during the
 year ended December 31, 2024.

(3) The
 fair value of RSUs granted on January 29, 2024 was $2.28 per share. A total of 12,500 restricted stock units were granted during
 the year ended December 31, 2024.

**Director Compensation Program**

Under the terms of our Director Compensation Program, the members of our Board of Directors for fiscal year 2025 are paid a fixed monthly fee, payable on a monthly basis, on the first day of each month, as follows:

---

| | |
|:---|:---|
| **Title** | **Annual Amount** |
| Chief Executive Officer | $60000 |
| Chief Financial Officer | $6000 |
| Other Non-Management Board Members | $12000 |

---

**Equity Compensation Plan Information**

The following table provides certain aggregate information with respect to all of our equity compensation plans in effect as of December 31, 2024.

---

| | | | |
|:---|:---|:---|:---|
| | **(a)** | **(b)** | **(c)** |
| <br>**Plan Category** | <br>**Number of**<br>**Securities to be**<br>**issued upon**<br>**exercise of**<br>**outstanding**<br>**options,**<br>**warrants and**<br>**rights** |<br><br>**Weighted**<br>**average**<br>**exercise price**<br>**of outstanding**<br>**options,**<br>**warrants,**<br>**and rights** | **Number of**<br>**Securities**<br>**remaining**<br>**available for**<br>**future issuance**<br>**under equity**<br>**compensation**<br>**plans (excluding**<br>**securities**<br>**reflected in**<br>**column (a))** |
| Total equity compensation plans approved by security holders<sup>(1)</sup> | 339000 | $13.46 | 483041 |
| Equity Compensation Plans Not Approved By Security Holders<sup>(2)</sup> |  | $- | 13333 |

---

(1) Consists
 of our 2018 Plan, our 2015 Plan, and our 2006 Plan. The Plans provide for the grant of incentive stock options, nonqualified stock
 options, stock appreciation rights, restricted stock, restricted stock units and performance units. There were no shares available
 for issuance, as of the date hereof, under the 2006 Plan or the 2015 Plan.

(2) Consists
 of our 2020 Plan. The 2020 Plan provides for the grant of nonqualified stock options, stock appreciation rights, restricted stock,
 restricted stock units and performance units.

**PAY VERSUS PERFORMANCE TABLE**

We are providing the following information pursuant to the SEC pay versus performance disclosure requirements set forth in Item 402(v) of SEC Regulation S-K (the "**Pay Versus Performance Rule**"), which requires disclosure of certain information about the relationships between our performance and the compensation of our named executive officers. The following table reports, for the three most-recent fiscal years, the compensation of our Chief Executive Officer and the average compensation of our other non-CEO named executive officers ("**Non-CEO Named Executive Officers**"), as well as the "Compensation Actually Paid" as calculated in accordance with the Pay Versus Performance Rule and certain performance measures required by the rule. The amounts reported as "Compensation Actually Paid" do not reflect the actual amount of compensation earned by or paid to our Chief Executive Officer or our Non-CEO Named Executive Officers and differ from the compensation amounts disclosed elsewhere in this proxy statement.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Year** | **Summary Compensation Table Total for CEO<sup>(1)(2)</sup>** | **Compensation Actually Paid to CEO<sup>(1)(3)</sup>** | **Aggregate Summary Compensation Table Total for Non-CEO Named Executive Officers<sup>(1)(2)</sup>** | **Aggregate Compensation Actually Paid to Non-CEO Named Executive Officers<sup>(1)(3)</sup>** | **Value of initial fixed $100 investment based on total shareholder return (TSR)<sup>(4)</sup>** | **Net Loss (in thousands)<sup>(5)</sup>** |
| **2024** | $585000 | $547706 | $363988 | $342889 | $0.64 | $(11212) |
| **2023** | $661049 | $65807 | $833233 | $172676 | $4.58 | $(22555) |
| **2022** | $763551 | $(77717) | $918518 | $(36347) | $17.15 | $(21198) |

---

__________________

(1) For
 each year shown, the CEO was Spiro Rombotis and the Non-CEO named executive officers (the "**NEO** s") were Paul McBarron
 and Mark Kirschbaum, MD.

(2) Amounts
 in this column represent the "Total" column set forth in the Summary Compensation Table ()"**SCT**") in
 the "Executive and Director Compensation" section. See the footnotes to the SCT for further details regarding the amounts
 in these columns.

(3) The
 dollar amounts reported in these columns represent the amounts of "compensation actually paid." The Amounts are computed
 in accordance with SEC rules by deducting and adding the following amounts from the "Total" column of the SCT (pursuant
 to SEC rules, fair value at each measurement date is computed in a manner consistent with the fair value methodology used to account
 for share-based payments in our financial statements under GAAP):

(4) Cumulative
 Total Shareholder Return ()"**TSR**") measures the cumulative value of $100 invested on the last trading day before
 the earliest fiscal year in the table, or December 31, 2021, including the reinvestment of dividends, through and including the end
 of the applicable fiscal year for which TSR is calculated, or December 31, 2022, December 31, 2023 and December 31, 2024. We did
 not pay dividends in the periods presented.

(5) The
 dollar amounts reported represent the amount of net loss reflected in the Company's audited financial statements for the applicable
 year.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Fiscal Year 2024** | **Fiscal Year 2024** | **Fiscal Year 2023** | **Fiscal Year 2023** | **Fiscal Year 2022** | **Fiscal Year 2022** |
|  | **CEO** | **NON- CEO NEO's** | **CEO** | **NON- CEO NEO's** | **CEO** | **NON- CEO NEO's** |
| **SCT Total Compensation** | **585000** | **363988** | **661049** | **833233** | **763551** | **918518** |
| Subtract Reported SCT Stock Option Award Value ($) | 0 | 0 | (100421) | (118167) | 0 | 0 |
| Add Year-end Fair Value of Unvested Awards Granted in the Applicable Fiscal Year ($) | 0 | 0 | 21961 | 26051 | 0 | 0 |
| Add Change in Fair Value of Awards Granted in Prior Years Outstanding and Unvested as of the Applicable Fiscal Year End ($) | (21986) | (13042) | (164307) | (172971) | (494733) | (545667) |
| Add Change in Fair Value of Awards Granted in Prior Years that Vested during the Applicable Year as of the Vesting Date | (21986) | (13042) | (352475) | (395470) | (346535) | (409198) |
| **Total Compensation Actually Paid** | 547706 | 342889 | **65807** | **172676** | **(77717)** | **(36347)** |

---

**Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return ("TSR")**

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and the Company's cumulative TSR over the three most recently completed fiscal years.

![](formdef14a_001.jpg)

***Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Income (Loss)* **

 ****

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Net Income (Loss) during the three most recently completed fiscal years.

![](formdef14a_002.jpg)

**REPORT OF AUDIT COMMITTEE**

The Audit Committee of the Board of Directors, which consists entirely of directors who meet the independence and experience requirements of The Nasdaq Capital Market, has furnished the following report:

The Audit Committee assists the Board of Directors in overseeing and monitoring the integrity of our financial reporting process, compliance with legal and regulatory requirements and the quality of internal and external audit processes. The Audit Committee's role and responsibilities are set forth in our charter adopted by the Board of Directors. The Audit Committee reviews and reassesses our charter annually and recommends any changes to the Board of Directors for approval.

In fiscal 2024, the Audit Committee met with management to consider the adequacy of the Company's internal controls and the objectivity of its financial reporting. The Audit Committee discussed these matters with the Company's independent registered public accounting firm and with appropriate Company financial personnel.

The Audit Committee is responsible for overseeing our overall financial reporting process, and for the appointment, retention, and oversight of the work of Bush & Associates CPA LLC ("**Bush & Associates**").

The Audit Committee reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2024 with management and Bush & Associates, our independent registered public accounting firm.

The Audit Committee discussed with Bush & Associates the matters required to be discussed in accordance with *Auditing Standard No. 18 — Communications with Audit Committees*.

The Audit Committee received written disclosures and the letter from Bush & Associates regarding its independence as required by applicable requirements of the Public Company Accounting Oversight Board regarding Bush & Associates' communications with the Audit Committee and the Audit Committee further discussed with Bush & Associates their independence. The Audit Committee also considered the status of pending litigation, taxation matters and other areas of oversight relating to the financial reporting and audit process that the Audit Committee determined appropriate.

Based on the Audit Committee's review of the audited consolidated financial statements and discussions with management and Bush & Associates, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 for filing with the SEC.

**2024 Members of the Audit Committee**

● Karin L. Walker (Chair)

● Dr. Samuel L. Barker

● Dr. Christopher S. Henney

● Dr. Robert J. Spiegel

**CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS**

Our Audit Committee reviews and approves in advance all related-party transactions. Except as described below, there have been no transactions during our last two fiscal years with our directors and officers and beneficial owners of more than 5% of our voting securities and their affiliates.

**PROPOSALS TO BE VOTED UPON BY HOLDERS OF COMMON STOCK**

**PROPOSAL 1:**

**ELECTION OF DIRECTORS**

**Background**

Under our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, as amended, the number of directors is fixed from time to time by the Board of Directors. We have a staggered Board of Directors comprised of three classes, and each director serves until the annual meeting in which his or her term expires. The Board of Directors has nominated each of the following five director nominees until their respective successors have been elected and qualified:

● Datuk Dr. Doris Wong is a Class 3 director and, if re-elected, would serve until our 2028 annual meeting,

● Kiu Cu Seng is a Class 2 director and, if re-elected, would serve until our 2027 annual meeting,

● Kwang Fock Chong is a Class 2 director and, if re-elected, would serve until our 2027 annual meeting,

● Dr. Satis Waran Nair Krishnan is a Class 1 director and, if re-elected, would serve until our 2026 annual meeting, and

● Inigo Angel Laurduraj is a Class 1 director and, if re-elected, would serve until our 2026 annual meeting.

Unless authority to vote for either of these nominees is withheld, proxies solicited by the Board of Directors will be voted FOR the re-election as director of each of Datuk Dr. Doris Wong, Kiu Cu Seng, Kwang Fock Chong, Dr. Satis Waran Nair Krishnan, and Inigo Angel Laurduraj.

In the event that either nominee shall become unable or unwilling to serve, proxies solicited by the Board of Directors will be voted for the election of such other person as the Board of Directors may recommend in his place. The Board of Directors has no reason to believe that either nominee will be unable or unwilling to serve.

**Required Vote**

A plurality of the votes cast at the annual meeting by the holders of our Common Stock is required to elect the nominees as director.

**Recommendation**

**THE BOARD OF DIRECTORS RECOMMENDS THE RE-ELECTION BY HOLDERS OF COMMON STOCK OF EACH OF DATUK DR. DORIS WONG, KIU CU SENG, KWANG FOCK CHONG, DR. SATIS WARAN NAIR KRISHNAN, AND INIGO ANGEL LAURDURAJ, AS DIRECTORS, AND PROXIES SOLICITED BY THE BOARD OF DIRECTORS WILL BE VOTED IN FAVOR THEREOF UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE.**

**PROPOSAL 2:**

**AMENDMENT TO 2018 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF**

**COMMON STOCK AVAILABLE FOR THE GRANT OF AWARDS BY 4,281,987 SHARES**

We are requesting that you vote to approve an amendment to the Cyclacel Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the "2018 Plan"). On April 22, 2025, the Board of Directors adopted a resolution approving, subject to approval by our stockholders, an amendment of the 2018 Equity Incentive Plan to increase the number of shares of Common Stock available for grant under the 2018 Plan by adding 4,281,987 shares. The 2018 Plan was previously approved by our stockholders at the 2018 annual meeting.

As of April 22, 2025, the equity overhang, represented by all outstanding awards plus those available for future grant under the 2018 Plan, was 0.2%. The equity overhang from all outstanding awards and shares available for issuance would be 1.3%, assuming approval of this Proposal. Equity overhang was calculated in each instance above as all shares issuable upon exercise of outstanding options plus shares available for future grant divided by (a) common shares outstanding plus (b) shares in the numerator.

**Key Considerations for Requesting Additional Shares**

In determining the number of shares to be authorized under the 2018 Plan, as proposed to be amended, the Board considered the following principal factors:

● <u>Number of Shares Available for Grant under Existing Plan</u>: As of the record date, 483,041 shares remained available for issuance under the 2018 Plan. Except for 13,333 shares that remained available under our 2020 Inducement Equity Incentive Plan, there were no shares available to grant under prior incentive plans.

● <u>Number of Outstanding Awards Under All Plans</u>: As of the record date, there were 339,000 outstanding stock options, which had a weighted average exercise price of $13.46 and a weighted average remaining contractual life of 7.82 years, and there were 32,666 RSU awards outstanding.

Our Board of Directors, the Compensation Development Committee and management all believe that the proposed amendment of the 2018 Plan is in the best interests of, and will provide long-term advantages to, us and our stockholders and recommends approval by our stockholders. The Board of Directors believes that the number of shares of common stock currently available for issuance under the 2018 Plan is insufficient in view of our compensation structure and strategy. The Board of Directors has concluded that our ability to attract, retain and motivate top quality employees is material to our success and would be enhanced by our continued ability to make grants under the 2018 Plan. The Board of Directors has directed that the proposal to approve the amendment of the 2018 Plan be submitted to the stockholders for approval at the 2025 Annual Meeting.

The following is a brief summary of the 2018 Plan, as amended by this Proposal, and is qualified in all respects by the specific language of the full text of the amended and restated 2018 Plan, a copy of which is attached as Appendix A to the Proxy Statement.

**Material Features of the 2018 Plan**

*Eligibility*. The 2018 Plan allows us, under the direction of our Compensation and Organization Development Committee, to make grants of stock options, restricted and unrestricted stock awards and other stock-based awards to employees, consultants and directors who, in the opinion of the Compensation and Organization Development Committee, are in a position to make a significant contribution to our long-term success. The purpose of these awards is to attract and retain key individuals, further align employee and stockholder interests, and to closely link compensation with Company performance. The 2018 Plan provides an essential component of the total compensation package, reflecting the importance that we place on aligning the interests of key individuals with those of our stockholders. All employees, directors and consultants of the Company and its affiliates are eligible to participate in the 2018 Plan. As of the record date, there were approximately 15 individuals eligible to participate.

*Shares Available for Issuance*. As of the record date 451,802 shares of our common stock were available for future awards under the 2018 Plan. In addition, if any awards granted under the 2018 Plan lapse or are canceled, the shares subject to those awards will again become available for awards under the 2018 Plan. As of the record date, 362,240 shares were subject to outstanding awards under the 2018 Plan. Generally, shares of common stock reserved for awards under the 2018 Plan that lapse or are canceled will be added back to the share reserve available for future awards. However, shares of common stock tendered in payment for an award or shares of common stock withheld for taxes will not be available again for grant. The 2018 Plan provides that no non-employee director participant may receive awards for more than an aggregate grant date fair value of $100,000 in any fiscal year. If our stockholders approve this proposal, an additional 4,281,987 shares of our common stock would be available for future awards under the 2018 Plan.

*Stock Options*. Stock options granted under the 2018 Plan may either be incentive stock options, which are intended to satisfy the requirements of Section 422 of the Internal Revenue Code of 1986, as amended, or the Code, or non-qualified stock options, which are not intended to meet those requirements. Incentive Stock Options may be granted to employees of the Company and its affiliates. Non-qualified options may be granted to employees, directors and consultants of the Company and its affiliates. The exercise price of a stock option may not be less than 100% of the fair market value of our common stock on the date of grant. If an incentive stock option is granted to an individual who owns more than 10% of the combined voting power of all classes of our capital stock, the exercise price may not be less than 110% of the fair market value of our common stock on the date of grant and the term of the incentive stock option may not be longer than five years. Non-qualified options may not have a term longer than ten years.

Award agreements for stock options include rules for the exercise of the stock options after termination of service. Options may not be exercised unless they are vested, and no option may be exercised after the end of the term set forth in the award agreement. Generally, stock options will be exercisable for three months after termination of service for any reason other than death or total and permanent disability, and for 12 months after termination of service on account of death or total and permanent disability but will not be exercisable if the termination of service was due to cause.

*Restricted Stock*. Restricted stock is common stock that is subject to restrictions, including a prohibition against transfer and a substantial risk of forfeiture, until the end of a "restricted period" during which the grantee must satisfy certain vesting conditions. If the grantee does not satisfy the vesting conditions by the end of the restricted period, the restricted stock is forfeited. During the restricted period, the holder of restricted stock has the rights and privileges of a regular stockholder, except that the restrictions set forth in the applicable award agreement apply. For example, the holder of the restricted stock may vote and receive dividends on the restricted shares; but he or she may not sell the shares until the restrictions are lifted.

*Restricted Stock Units*. Restricted stock units are phantom shares that vest in accordance with terms and conditions established by the Board of Directors or the Compensation and Organization Development Committee and when the applicable restrictions lapse, the grantee shall be entitled to receive a payout in cash, shares or a combination thereof based on the number of restricted stock units, as specified in the award agreement.

*Other Stock-Based Awards*. The 2018 Plan also authorizes the grant of other types of stock-based compensation including, but not limited to phantom stock awards, stock appreciation rights and stock unit awards. Our Compensation and Organization Development Committee may award such stock-based awards subject to such conditions and restrictions as it may determine however each stock appreciation right shall have an exercise price which shall not be less than the fair market value of our common stock on the date of grant and shall terminate no more than ten years from the date of grant. These conditions and restrictions may include continued employment with us through a specified restricted period.

*Plan Administration*. In accordance with the terms of the 2018 Plan, our Board of Directors has authorized our Compensation and Organization Development Committee to administer the 2018 Plan. The Compensation and Organization Development Committee may delegate part of its authority and powers under the 2018 Plan to one or more of our directors and/or officers, but only the Compensation and Organization Development Committee can make awards to participants who are directors or executive officers of the Company. In accordance with the provisions of the 2018 Plan, our Compensation and Organization Development Committee determines the terms of awards, including:

● employees, directors and consultants will be granted awards;

● the number of shares subject to each award;

● the vesting provisions of each award;

● the termination or cancellation provisions applicable to awards; and

● all other terms and conditions upon which each award may be granted in accordance with the 2018 Plan.

In addition, our Compensation and Organization Development Committee may, in its discretion, amend any term or condition of an outstanding award provided (i) such term or condition as amended is permitted by the 2018 Plan, and (ii) any such amendment shall be made only with the consent of the participant to whom such award was made, if the amendment is adverse to the participant; and provided, further, that, without the prior approval of our stockholders, options will not be repriced, replaced or regranted through cancellation or by lowering the exercise price of a previously granted award and will not be exchanged for another type of award or cash.

*Stock Dividends and Stock Splits*. If our common stock shall be subdivided or combined into a greater or smaller number of shares or if we issue any shares of common stock as a stock dividend, the number of shares of our common stock deliverable upon exercise of an option or upon vesting of an award shall be appropriately increased or decreased proportionately, and appropriate adjustments shall be made in the purchase price per share to reflect such subdivision, combination or stock dividend.

*Corporate Transactions*. Upon a merger or other reorganization event, our Board of Directors, may, in its sole discretion, take any one or more of the following actions pursuant to the 2018 Plan, as to some or all outstanding awards:

● provide that all outstanding options shall be assumed or substituted by the successor corporation;

● upon written notice to a participant provide that the participant's unexercised options will terminate immediately prior to the consummation of such transaction unless exercised by the participant;

● in the event of a merger pursuant to which holders of our common stock will receive a cash payment for each share surrendered in the merger, make or provide for a cash payment to the participants equal to the difference between the merger price times the number of shares of our common stock subject to such outstanding options, and the aggregate exercise price of all such outstanding options, in exchange for the termination of such options;

● provide that outstanding awards shall be assumed or substituted by the successor corporation, become realizable or deliverable, or restrictions applicable to an award will lapse, in whole or in part, prior to or upon the merger or reorganization event; and

● with respect to stock grants and in lieu of any of the foregoing, the Board of Directors or an authorized committee may provide that, upon consummation of the transaction, each outstanding stock grant shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation of such transaction to a holder of the number of shares of common stock comprising such award (to the extent such stock grant is no longer subject to any forfeiture or repurchase rights then in effect or, at the discretion of the Board of Directors or an authorized committee, all forfeiture and repurchase rights being waived upon such transaction).

However, in the event that the successor corporation refuses to assume or substitute an award:

● awards consisting of options, SARs and rights to purchase restricted stock will become fully vested and immediately exercisable, including awards that would not otherwise have become vested or exercisable; and

● all other awards will become fully earned and eligible to receive a payout.

*Amendment and Termination*. The 2018 Plan may be amended by our stockholders. It may also be amended by our Board of Directors, provided that any amendment approved by our Board of Directors, which is of a scope that requires stockholder approval as required by the rules of The Nasdaq Stock Market, in order to ensure favorable federal income tax treatment for any incentive stock options under Code Section 422, or for any other reason is subject to obtaining such stockholder approval. However, no such action may adversely affect any rights under any outstanding award without the holder's consent.

*Duration of Plan*. The 2018 Plan will expire, by its terms, on March 29, 2028.

**Federal Income Tax Considerations**

The material federal income tax consequences of the issuance and exercise of stock options and other awards under the 2018 Plan, based on the current provisions of the Code and regulations, are as follows. Changes to these laws could alter the tax consequences described below. This summary assumes that all awards granted under the 2018 Plan are exempt from or comply with, the rules under Section 409A of the Code related to nonqualified deferred compensation.

---

| | |
|:---|:---|
| **Incentive Stock Option:** | Incentive stock options are intended to qualify for treatment under Section 422 of the Code. An incentive stock option does not result in taxable income to the optionee or deduction to us at the time it is granted or exercised, provided that no disposition is made by the optionee of the shares acquired pursuant to the option within two years after the date of grant of the option nor within one year after the date of issuance of shares to the optionee (referred to as the "ISO holding period"). However, the difference between the fair market value of the shares on the date of exercise and the option price will be an item of tax preference includible in "alternative minimum taxable income" of the optionee. Upon disposition of the shares after the expiration of the ISO holding period, the optionee will generally recognize long term capital gain or loss based on the difference between the disposition proceeds and the option price paid for the shares. If the shares are disposed of, prior to the expiration of the ISO holding period, the optionee generally will recognize taxable compensation, and we will have a corresponding deduction, in the year of the disposition, equal to the excess of the fair market value of the shares on the date of exercise of the option over the option price. Any additional gain realized on the disposition will normally constitute capital gain. If the amount realized upon such a disqualifying disposition is less than the fair market value of the shares on the date of exercise, the amount of compensation income will be limited to the excess of the amount realized over the optionee's adjusted basis in the shares. |
| **Non-Qualified Options:** | Options otherwise qualifying as incentive stock options, to the extent the aggregate fair market value of shares with respect to which such options are first exercisable by an individual in any calendar year exceeds $100,000, and options designated as non-qualified options will be treated as options that are not incentive stock options. A non-qualified option ordinarily will not result in income to the optionee or deduction to us at the time of grant. The optionee will recognize compensation income at the time of exercise of such non-qualified option in an amount equal to the excess of the value of the shares over the option price per share. Such compensation income of optionees may be subject to withholding taxes, and a deduction may then be allowable to us in an amount equal to the optionee's compensation income. |
|  | An optionee's initial basis in shares, so acquired, will be the amount paid on exercise of the non-qualified option plus the amount of any corresponding compensation income. Any gain or loss as a result of a subsequent disposition of the shares, so acquired, will be capital gain or loss. |
| **Stock Grants:** | With respect to stock grants under the 2018 Plan that result in the issuance of shares that are either not restricted as to transferability or not subject to a substantial risk of forfeiture, the grantee must generally recognize ordinary income equal to the fair market value of shares received. We generally will be entitled to a deduction in an amount equal to the ordinary income recognized by the grantee. |
|  | With respect to stock grants involving the issuance of shares that are restricted as to transferability and subject to a substantial risk of forfeiture, the grantee must generally recognize ordinary income equal to the fair market value of the shares received at the first time the shares become transferable or are not subject to a substantial risk of forfeiture, whichever occurs earlier. A grantee may elect to be taxed at the time of receipt of shares rather than upon lapses of restrictions on transferability or substantial risk of forfeiture, but if the grantee subsequently forfeits such shares, the grantee would not be entitled to any tax deduction, including as a capital loss, for the value of the shares on which he previously paid tax. If such an election is desired, the grantee must file such an election with the Internal Revenue Service within 30 days of the receipt of the shares. We generally will be entitled to a deduction in an amount equal to the ordinary income recognized by the grantee. |
| **Stock Units:** | The grantee recognizes no income until the issuance of the shares. At that time, the grantee must generally recognize ordinary income equal to the fair market value of the shares received. We generally will be entitled to a deduction in an amount equal to the ordinary income recognized by the grantee. |

---

**Plan Benefits**

Since the adoption of the 2018 Plan through the record date, we have granted the following stock options and restricted stock units under the 2018 Plan to the individuals and groups listed below. In all cases, the securities underlying such equity awards were shares of our common stock. Since the adoption of the 2018 Plan through the record date, we have granted the following stock options and restricted stock units under the 2018 Plan to the individuals and groups listed below. In all cases, the securities underlying such equity awards were shares of our common stock.

---

| | |
|:---|:---|
| **Name and Position** | **Number of Shares** |
| *Named Executive Officers:* |  |
| Datuk Dr. Doris Wong |  |
| Kiu Cu Seng |  |
| All current executive officers as a group |  |
| All current directors who are not executive officers as a group |  |
| *Each nominee for election as a director:* |  |
| Datuk Dr. Doris Wong |  |
| Kiu Cu Seng |  |
| Inigo Angel Laurduraj |  |
| Kwang Fock Chong |  |
| Dr. Satis Waran Nair Krishnan |  |
| Each associate of any executive officers, current directors or director nominees |  |
| *Each other person who received or is to receive 5% of awards:* |  |
| All employees, including all current officers who are not executive officers, as a group |  |

---

**New Plan Benefits**

Other than the annual grant of stock options or restricted stock units, or any initial grant of restricted stock units to our non-employee directors, the amounts of future grants under the 2018 Plan are not determinable as awards under the 2018 Plan and will be granted at the sole discretion of the Compensation and Organization Development Committee, or other delegated persons and we cannot determine at this time either the persons who will receive awards under the 2018 Plan or the amount or types of any such awards. On April 23, 2025, the closing market price per share of our common stock was $0.22, as reported by the Nasdaq Stock Market.

**Required Vote**

The Board of Directors has recommended adopting the amendment to the 2018 Plan. The affirmative vote of a majority of the votes cast at the annual meeting is required to approve the amendment to the 2018 Plan.

**Recommendation**

**THE BOARD OF DIRECTORS RECOMMENDS APPROVAL OF THE AMENDMENT TO THE 2018 PLAN. PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR OF THE AMENDMENT UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE.**

**PROPOSAL 3:**

**ADVISORY VOTE ON APPROVAL OF EXECUTIVE COMPENSATION AS DISCLOSED IN THIS PROXY**

**STATEMENT**

**General**

The Dodd-Frank Wall Street Reform and Consumer Protection of 2010 (the "**Dodd-Frank Act**") enables our stockholders to vote to approve on an advisory and non-binding basis, the compensation of our named executive officers as described in the Executive Officer and Director Compensation section of this proxy statement, the compensation tables and related material contained in this proxy statement. This "say-on-pay" proposal gives our stockholders the opportunity to express their views on our overall compensation decisions and policies. The Dodd-Frank Act also requires an advisory vote on executive compensation at least once every three years.

Stockholders are urged to read the Executive and Director Compensation section of this proxy statement, which discusses how our compensation policies and procedures implement our compensation philosophy. The Compensation and Organization Development Committee and the Board of Directors believe that these policies and procedures are effective in implementing our compensation philosophy and in achieving its goals.

As more fully described in the Executive and Director Compensation section of this proxy statement, existing employment contracts provide for the bulk of the compensation of our executives. A significant portion, however, is discretionary and determined by the Compensation and Organization Development Committee on an annual basis. Historically (but subject to change in the future), much of the additional or bonus compensation and equity awards have been based on specific numeric and weighted criteria for these officers. On an annual basis, the Committee reviews and approves the objectives for each officer's goals and the following year analyzes to what extent the objectives have been achieved. The Committee then determines the resulting additional compensation and equity grants. In so doing, the Committee considers the interest of the stockholders, current market practices, the clinical goals of the Company, the need to motivate its officers, and other criteria. The Committee has also considered the extensive experience of our executives in the biotech industry as well as their related and relevant activities prior to their entry into the biotech industry. These considerations inform the Committee's assessment of the type of compensation program and incentives that are appropriate and necessary to attract, motivate and retain the named executives who are crucial to the Company's long-term success.

Because your vote is advisory, it will not be binding on our Compensation and Organization Development Committee or our Board of Directors, nor will it directly affect or otherwise limit any compensation or award arrangements that have already been granted to any of the named executive officers. However, the Compensation and Organization Development Committee and the Board will review the voting results and take them into consideration when making future decisions regarding executive compensation.

In accordance with the rules adopted by the SEC, the following resolution, commonly known as a "say- on-pay" vote, is being submitted for a stockholder vote at the 2025 Annual Meeting:

"RESOLVED, that the compensation paid to the named executive officers of Cyclacel Pharmaceuticals, Inc., as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Executive Officer and Director Compensation section of the proxy statement for the 2025 Annual Meeting, the compensation tables and the related material disclosed in the proxy statement, is hereby APPROVED."

**Required Vote**

The affirmative vote of a majority of the votes cast at the annual meeting is required to approve, on an advisory basis, this resolution.

**Recommendation**

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR OF SUCH APPROVAL UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE.**

**CODE OF BUSINESS CONDUCT AND ETHICS**

We have adopted a Code of Business Conduct and Ethics that applies to all of our officers, directors, and employees, including our principal executive officer, principal financial officer, principal accounting officer, and controller, or persons performing similar functions, which is posted on our website. Our Code of Business Conduct and Ethics is a "code of ethics," as defined in Item 406(b) of Regulation S-K. We will make any legally required disclosures regarding amendments to, or waivers of, provisions of our Code of Business Conduct and Ethics on our website where our Code of Business Conduct and Ethics can be found at: e8e96faf-768b-4ba4-974a-826aba6bb9e3.

In addition to being posted on Cyclacel's website, the text of the Code of Business Conduct and Ethics will be made available to stockholders without charge, upon request, in writing to the Corporate Secretary at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 59200, Attention: Kiu Cu Seng, Chief Financial Officer, Executive Director and Secretary.

Disclosure regarding any amendments to, or waivers from, provisions of the code of conduct and ethics that apply to our directors, principal executive and financial officers will be included in a Current Report on Form 8-K within four business days following the date of the amendment or waiver, unless website posting of such amendments or waivers is then permitted by the rules of The Nasdaq Stock Market.

**OTHER MATTERS**

The Board of Directors knows of no other business which will be presented to the annual meeting. If any other business is properly brought before the annual meeting, proxies will be voted in accordance with the judgment of the persons voting the proxies.

**STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR**

To be considered for inclusion in the proxy statement relating to our 2025 Annual Meeting of Stockholders, we must receive stockholder proposals (other than for director nominations) by no later than December 15, 2024. To be considered for presentation at the 2025 Annual Meeting of Stockholders, although not included in the proxy statement, proposals (including director nominations) must be received no earlier than February 13, 2025 and no later than March 15, 2025. In addition to satisfying the foregoing advance notice requirements, to comply with the universal proxy rules under the Exchange Act, stockholders who intend to solicit proxies in support of director nominees other than the Company's nominees must follow the requirements set forth in Rule 14a-19 as promulgated under the Exchange Act.

Proposals that are not received in a timely manner will not be presented or voted on at the 2025 Annual Meeting of Stockholders. If a proposal is received on time, the proxies that management solicits for the meeting may still exercise discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. All stockholder proposals should be marked for the attention of Secretary, Cyclacel Pharmaceuticals, Inc., Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 59200.

**Our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as amended (other than exhibits thereto), filed with the SEC, which provides additional information about us, is available on the Internet at www.cyclacel.com and is available in paper form to beneficial owners of our stock without charge upon written request to Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 59200, Attention: Kiu Cu Seng, Chief Financial Officer, Executive Director and Secretary.**

**Appendix A**

**2018 EQUITY INCENTIVE PLAN, AS AMENDED**

**Effective June 30, 2025**

1. DEFINITIONS.

Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Cyclacel Pharmaceuticals, Inc. 2018 Equity Incentive Plan, have the following meanings:

"Administrator" means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the Administrator means the Committee.

"Affiliate" means a corporation, which, for purposes of Section 424 of the Code, is a parent or subsidiary of the Company, direct or indirect.

"Agreement" means a written or electronic document setting forth the terms of a Stock Right delivered pursuant to the Plan in such form as the Administrator shall approve.

"Board of Directors" means the Board of Directors of the Company.

"Cause" means, with respect to a Participant (a) dishonesty with respect to the Company or any Affiliate, (b) insubordination, substantial malfeasance or non-feasance of duty, (c) unauthorized disclosure of confidential information, (d) breach by a Participant of any provision of any employment, consulting, advisory, nondisclosure, non-competition or similar agreement between the Participant and the Company or any Affiliate, and (e) conduct substantially prejudicial to the business of the Company or any Affiliate; provided, however, that any provision in an agreement between a Participant and the Company or an Affiliate, which contains a conflicting definition of Cause for termination and which is in effect at the time of such termination, shall supersede this definition with respect to that Participant. The determination of the Administrator as to the existence of Cause will be conclusive on the Participant and the Company.

"Change of Control" means the occurrence of any of the following events: (a) any person, partnership, joint venture, corporation or other entity, or two or more of any of the foregoing acting as a group (or any "person" within the meaning of Sections 13(d) and 14(d) of the Exchange Act), other than the Company, an Affiliate, or an employee benefit plan (or related trust) of the Company or an Affiliate, become(s) the "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act) of 30% or more of the then- outstanding voting stock of the Company; (b) during any period of two consecutive years, individuals who at the beginning of such period constitute the Board of Directors (together with any new director whose election by the Board of Directors or whose nomination for election by the Company's stockholders, was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of such period or whose election or nomination for election was previously so approved) cease for any reason to constitute a majority of the directors then in office; (c) all or substantially all of the business of the Company is disposed of pursuant to a merger, consolidation or other transaction in which the Company is not the surviving corporation or the Company combines with another company and is the surviving corporation (unless the stockholders of the Company immediately following such merger, consolidation, combination, or other transaction beneficially own, directly or indirectly, more than 50% of the aggregate voting stock or other ownership interests of (x) the entity or entities, if any, that succeed to the business of the Company or (y) the combined company); (d) the Company is a party to a merger, consolidation, sale of assets or other reorganization, or a proxy contest, as a consequence of which the Board of Directors in office immediately prior to such transaction or event constitutes less than a majority of the Board of Directors thereafter; or (e) the stockholders of the Company approve a sale of all or substantially all of the assets of the Company or a liquidation or dissolution of the Company; provided, that if any payment or benefit payable hereunder upon or following a Change of Control would be required to comply with the limitations of Section 409A(a)(2)(A)(v) of the Code in order to avoid an additional tax under Section 409A of the Code, such payment or benefit shall be made only if such Change of Control constitutes a change in ownership or control of the Company, or a change in ownership of the Company's assets in accordance with Section 409A of the Code.

"Code" means the United States Internal Revenue Code of 1986, as amended including any successor statute, regulation and guidance thereto.

"Committee" means the committee of the Board of Directors to which the Board of Directors has delegated power to act under or pursuant to the provisions of the Plan.

"Common Stock" means shares of the Company's common stock, $0.001 par value per share.

"Company" means Cyclacel Pharmaceuticals, Inc., a Delaware corporation.

"Consultant" means any natural person who is an advisor or consultant who provides bonafide services to the Company or its Affiliates, provided that such services are not in connection with the offer or sale of securities in a capital raising transaction, and do not directly or indirectly promote or maintain a market for the Company's or its Affiliates' securities.

"Corporate Transaction" means a merger, consolidation, or sale of all or substantially all of the Company's assets or the acquisition of all of the outstanding voting stock of the Company in a single transaction or a series of related transactions by a single entity other than a transaction to merely change the state of incorporation.

"Disability" or "Disabled" means permanent and total disability as defined in Section 22(e)(3) of the Code.

"Employee" means any employee of the Company or of an Affiliate (including, without limitation, an employee who is also serving as an officer or director of the Company or of an Affiliate), designated by the Administrator to be eligible to be granted one or more Stock Rights under the Plan.

"Exchange Act" means the United States Securities Exchange Act of 1934, as amended.

"Fair Market Value" of a Share of Common Stock means:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) If
 the Common Stock is listed on a national securities exchange or traded in the over-the-counter market and sales prices are regularly
 reported for the Common Stock, the closing or, if not applicable, the last price of the Common Stock on the composite tape or other
 comparable reporting system for the trading day on the applicable date and if such applicable date is not a trading day, the last
 market trading day prior to such date;

b) If
 the Common Stock is not traded on a national securities exchange but is traded on the over-the- counter market, if sales prices are
 not regularly reported for the Common Stock for the trading day referred to in clause (1), and if bid and asked prices for the Common
 Stock are regularly reported, the mean between the bid and the asked price for the Common Stock at the close of trading in the over-the-counter
 market for the trading day on which Common Stock was traded on the applicable date and if such applicable date is not a trading day,
 the last market trading day prior to such date; and

c) If
 the Common Stock is neither listed on a national securities exchange nor traded in the over-the- counter market, such value as the
 Administrator, in good faith, shall determine in compliance with applicable laws.

"ISO" means an option intended to qualify as an incentive stock option under Section 422 of the Code. Non-Qualified Option means an option which is not intended to qualify as an ISO.

"Option" means an ISO or Non-Qualified Option granted under the Plan.

"Participant" means an Employee, director or Consultant of the Company or an Affiliate to whom one or more Stock Rights are granted under the Plan. As used herein, "Participant" shall include "Participant's Survivors" where the context requires.

"Performance-Based Award" means a Stock Grant or Stock-Based Award which vests based on the attainment of written Performance Goals as set forth in Paragraph 9 hereof.

"Performance Goals" means performance goals determined by the Committee in its sole discretion and set forth in an Agreement. The satisfaction of Performance Goals shall be subject to certification by the Committee. The Committee has the authority to take appropriate action with respect to the Performance Goals (including, without limitation, making adjustments to the Performance Goals or determining the satisfaction of the Performance Goals in connection with a Corporate Transaction) provided that any such action does not otherwise violate the terms of the Plan.

"Plan" means this Cyclacel Pharmaceuticals, Inc. 2018 Equity Incentive Plan. Securities Act means the United States Securities Act of 1933, as amended.

"Shares" means shares of the Common Stock as to which Stock Rights have been or may be granted under the Plan or any shares of capital stock into which the Shares are changed or for which they are exchanged within the provisions of Paragraph 3 of the Plan. The Shares issued under the Plan may be authorized and unissued shares or shares held by the Company in its treasury, or both.

"Stock-Based Award" means a grant by the Company under the Plan of an equity award or an equity based award, which is not an Option or a Stock Grant.

"Stock Grant" means a grant by the Company of Shares under the Plan.

"Stock Right" means a right to Shares or the value of Shares of the Company granted pursuant to the Plan-an ISO, a Non-Qualified Option, a Stock Grant or a Stock-Based Award.

"Survivor" means a deceased Participant's legal representatives and/or any person or persons who acquired the Participant's rights to a Stock Right by will or by the laws of descent and distribution.

2. PURPOSES OF THE PLAN.

The Plan is intended to encourage ownership of Shares by Employees and directors of and certain Consultants to the Company and its Affiliates in order to attract and retain such people, to induce them to work for the benefit of the Company or of an Affiliate and to provide additional incentive for them to promote the success of the Company or of an Affiliate. The Plan provides for the granting of ISOs, Non- Qualified Options, Stock Grants and Stock-Based Awards.

3. SHARES SUBJECT TO THE PLAN.

&nbsp;&nbsp;&nbsp;&nbsp;a) The
 number of Shares which may be issued from time to time pursuant to this Plan shall be the sum of: (i) 3,535,000 shares of Common
 Stock and (ii) any shares of Common Stock that are represented by awards granted under the Company's 2015 Equity Incentive
 Plan and the Company's Amended and Restated 2006 Equity Incentive Plan that are forfeited, expire or are cancelled without
 delivery of shares of Common Stock or which result in the forfeiture of shares of Common Stock back to the Company on or after May
 31, 2018, or the equivalent of such number of Shares after the Administrator, in its sole discretion, has interpreted the effect
 of any stock split, stock dividend, combination, recapitalization or similar transaction in accordance with Paragraph 25 of this
 Plan; provided, however, that no more than 35,494 Shares shall be added to the Plan pursuant to subsection (ii).

b) If
 an Option ceases to be "outstanding", in whole or in part (other than by exercise), or if the Company shall reacquire
 (at not more than its original issuance price) any Shares issued pursuant to a Stock Grant or Stock-Based Award, or if any Stock
 Right expires or is forfeited, cancelled, or otherwise terminated or results in any Shares not being issued, the unissued or reacquired
 Shares which were subject to such Stock Right shall again be available for issuance from time to time pursuant to this Plan. Notwithstanding
 the foregoing, if a Stock Right is exercised, in whole or in part, by tender or withholding of Shares or if the Company or an Affiliate's
 tax withholding obligation is satisfied by the tender or withholding of Shares, the number of Shares deemed to have been issued under
 the Plan for purposes of the limitation set forth in Paragraph 3(a) above shall be the number of Shares that were subject to the
 Stock Right or portion thereof, and not the net number of Shares actually issued. In addition, Shares repurchased by the Company
 with the proceeds of the option exercise price may not be reissued under the Plan. However, in the case of ISOs, the foregoing provisions
 shall be subject to any limitations under the Code.

4. ADMINISTRATION OF THE PLAN.

The Administrator of the Plan will be the Board of Directors, except to the extent the Board of Directors delegates its authority to the Committee, in which case the Committee shall be the Administrator. Subject to the provisions of the Plan, the Administrator is authorized to:

&nbsp;&nbsp;&nbsp;&nbsp;a) Interpret
 the provisions of the Plan and all Stock Rights and to make all rules and determinations which it deems necessary or advisable for
 the administration of the Plan;

b) Determine
 which Employees, directors and Consultants shall be granted Stock Rights;

c) Determine
 the number of Shares for which a Stock Right or Stock Rights shall be granted, provided however that in no event shall Stock Rights
 to be granted to any non-employee director under the Plan in any calendar year exceed an aggregate grant date fair value of $100,000
 except that the foregoing limitation shall not apply to (i) awards made pursuant to an election by a non-employee director to receive
 an award in lieu of cash for all or a portion of cash fees to be received for service on the Board or any Committee thereof and (ii)
 in connection with a non-employee director initially joining the Board of Directors;

---

| | |
|:---|:---|
| d) | Specify the terms and conditions upon which a Stock Right or Stock Rights may be granted; |
| e) | Amend any term or condition of any outstanding Stock Right, other than reducing the exercise price or purchase price or extending the expiration date of an Option, provided that (i) such term or condition as amended is not prohibited by the Plan; (ii) any such amendment shall not impair the rights of a Participant under any Stock Right previously granted without such Participant's consent or in the event of death of the Participant the Participant's Survivors; and (iii) any such amendment shall be made only after the Administrator determines whether such amendment would cause any adverse tax consequences to the Participant, including, but not limited to, the annual vesting limitation contained in Section 422(d) of the Code and described in Paragraph 6(b)(iv) below with respect to ISOs and pursuant to Section 409A of the Code; |
| f) | Determine and make any adjustments in the Performance Goals included in any Performance-Based Awards; and |
| g) | Adopt any sub-plans applicable to residents of any specified jurisdiction as it deems necessary or appropriate in order to comply with or take advantage of any tax or other laws applicable to the Company, any Affiliate or to Participants or to otherwise facilitate the administration of the Plan, which sub-plans may include additional restrictions or conditions applicable to Stock Rights or Shares issuable pursuant to a Stock Right; |
|  | provided, however, that all such interpretations, rules, determinations, terms and conditions shall be made and prescribed in the context of potential tax consequences under Section 409A of the Code and preserving the tax status under Section 422 of the Code of those Options which are designated as ISOs. Subject to the foregoing, the interpretation and construction by the Administrator of any provisions of the Plan or of any Stock Right granted under it shall be final, unless otherwise determined by the Board of Directors, if the Administrator is the Committee. In addition, if the Administrator is the Committee, the Board of Directors may take any action under the Plan that would otherwise be the responsibility of the Committee. |
|  | To the extent permitted under applicable law, the Board of Directors or the Committee may allocate all or any portion of its responsibilities and powers to any one or more of its members and may delegate all or any portion of its responsibilities and powers to any other person selected by it. The Board of Directors or the Committee may revoke any such allocation or delegation at any time. Notwithstanding the foregoing, only the Board of Directors or the Committee shall be authorized to grant a Stock Right to any director of the Company or to any "officer" of the Company as defined by Rule 16a-1 under the Exchange Act. |

---

5. ELIGIBILITY FOR PARTICIPATION.

The Administrator will, in its sole discretion, name the Participants in the Plan; provided, however, that each Participant must be an Employee, director or Consultant of the Company or of an Affiliate at the time a Stock Right is granted. Notwithstanding the foregoing, the Administrator may authorize the grant of a Stock Right to a person not then an Employee, director or Consultant of the Company or of an Affiliate; provided, however, that the actual grant of such Stock Right shall be conditioned upon such person becoming eligible to become a Participant at or prior to the time of the execution of the Agreement evidencing such Stock Right. ISOs may be granted only to Employees who are deemed to be residents of the United States for tax purposes. Non-Qualified Options, Stock Grants and Stock-Based Awards may be granted to any Employee, director or Consultant of the Company or an Affiliate. The granting of any Stock Right to any individual shall neither entitle that individual to, nor disqualify him or her from, participation in any other grant of Stock Rights or any grant under any other benefit plan established by the Company or any Affiliate for Employees, directors or Consultants.

6. TERMS AND CONDITIONS OF OPTIONS.

Each Option shall be set forth in an Option Agreement, duly executed by the Company and, to the extent required by law or requested by the Company, by the Participant. The Administrator may provide that Options be granted subject to such terms and conditions, consistent with the terms and conditions specifically required under this Plan, as the Administrator may deem appropriate including, without limitation, subsequent approval by the shareholders of the Company of this Plan or any amendments thereto. The Option Agreements shall be subject to at least the following terms and conditions:

i. Non-Qualified
 Options: Each Option intended to be a Non-Qualified Option shall be subject to the terms and conditions which the Administrator determines
 to be appropriate and in the best interest of the Company, subject to the following minimum standards for any such Non-Qualified
 Option:

i. Exercise
 Price: Each Option Agreement shall state the exercise price (per share) of the Shares covered by each Option, which exercise price
 shall be determined by the Administrator and shall be at least equal to the Fair Market Value per share of the Common Stock on the
 date of grant of the Option.

ii. Number
 of Shares: Each Option Agreement shall state the number of Shares to which it pertains.

iii. Vesting:
 Each Option Agreement shall state the date or dates on which it first is exercisable and the date after which it may no longer be
 exercised, and may provide that the Option rights accrue or become exercisable in installments over a period of months or years,
 or upon the occurrence of certain performance conditions or the attainment of stated goals or events.

iv. Additional
 Conditions: Exercise of any Option may be conditioned upon the Participant's execution of a shareholders agreement in a form
 satisfactory to the Administrator providing for certain protection for the Company and its other shareholders, including requirements
 that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. The
 Participant's or the Participant's Survivors' right to sell or transfer the Shares may be restricted; and

B. The
 Participant or the Participant's Survivors may be required to execute letters of investment intent and must also acknowledge
 that the Shares will bear legends noting any applicable restrictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v. Term
 of Option: Each Option shall terminate not more than ten years from the date of the grant or at such earlier time as the Option Agreement
 may provide.

ii. ISOs:
 Each Option intended to be an ISO shall be issued only to an Employee who is deemed to be a resident of the United States for tax
 purposes, and shall be subject to the following terms and conditions, with such additional restrictions or changes as the Administrator
 determines are appropriate but not in conflict with Section 422 of the Code and relevant regulations and rulings of the Internal
 Revenue Service:

i. Minimum
 Standards: The ISO shall meet the minimum standards required of Non- Qualified Options, as described in Paragraph 6(a) above, except
 clause (i) and (v) thereunder.

ii. Exercise
 Price: Immediately before the ISO is granted, if the Participant owns, directly or by reason of the applicable attribution rules
 in Section 424(d) of the Code:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. 10%
 or less of the total combined voting power of all classes of stock of the Company or an Affiliate, the exercise price per share of
 the Shares covered by each ISO shall not be less than 100% of the Fair Market Value per share of the Common Stock on the date of
 grant of the Option; or

B. More
 than 10% of the total combined voting power of all classes of stock of the Company or an Affiliate, the exercise price per share
 of the Shares covered by each ISO shall not be less than 110% of the Fair Market Value per share of the Common Stock on the date
 of grant of the Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. Term
 of Option: For Participants who own:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. 10%
 or less of the total combined voting power of all classes of stock of the Company or an Affiliate, each ISO shall terminate not more
 than ten years from the date of the grant or at such earlier time as the Option Agreement may provide; or

B. More
 than 10% of the total combined voting power of all classes of stock of the Company or an Affiliate, each ISO shall terminate not
 more than five years from the date of the grant or at such earlier time as the Option Agreement may provide.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. Limitation
 on Yearly Exercise: The Option Agreements shall restrict the amount of ISOs which may become exercisable in any calendar year (under
 this or any other ISO plan of the Company or an Affiliate) so that the aggregate Fair Market Value (determined on the date each ISO
 is granted) of the stock with respect to which ISOs are exercisable for the first time by the Participant in any calendar year does
 not exceed $100,000.

7. TERMS AND CONDITIONS OF STOCK GRANTS.

Each Stock Grant to a Participant shall state the principal terms in an Agreement duly executed by the Company and, to the extent required by law or requested by the Company, by the Participant. The Agreement shall be in a form approved by the Administrator and shall contain terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company, subject to the following minimum standards:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Each
 Agreement shall state the purchase price per share, if any, of the Shares covered by each Stock Grant, which purchase price shall
 be determined by the Administrator but shall not be less than the minimum consideration required by the Delaware General Corporation
 Law, if any, on the date of the grant of the Stock Grant;

(b) Each
 Agreement shall state the number of Shares to which the Stock Grant pertains;

(c) Each
 Agreement shall include the terms of any right of the Company to restrict or reacquire the Shares subject to the Stock Grant, including
 the time period or attainment of Performance Goals or such other performance criteria upon which such rights shall accrue and the
 purchase price therefor, if any; and

(d) Dividends
 (other than stock dividends to be issued pursuant to Section 25 of the Plan) may accrue but shall not be paid prior to the time,
 and may be paid only to the extent that the restrictions or rights to reacquire the Shares subject to the Stock Grant lapse.

8. TERMS AND CONDITIONS OF OTHER STOCK-BASED AWARDS.

The Administrator shall have the right to grant other Stock-Based Awards based upon the Common Stock having such terms and conditions as the Administrator may determine, including, without limitation, the grant of Shares based upon certain conditions, the grant of securities convertible into Shares and the grant of stock appreciation rights, phantom stock awards or stock units. The principal terms of each Stock- Based Award shall be set forth in an Agreement, duly executed by the Company and, to the extent required by law or requested by the Company, by the Participant. The Agreement shall be in a form approved by the Administrator and shall contain terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company. Each Agreement shall include the terms of any right of the Company including the right to terminate the Stock-Based Award without the issuance of Shares, the terms of any vesting conditions, Performance Goals or events upon which Shares shall be issued, provided that dividends (other than stock dividends to be issued pursuant to Section 25 of the Plan) or dividend equivalents may accrue but shall not be paid prior to and may be paid only to the extent that the Shares subject to the Stock-Based Award vest. Under no circumstances may the Agreement covering stock appreciation rights (a) have an exercise or base price (per share) that is less than the Fair Market Value per share of Common Stock on the date of grant or (b) expire more than ten years following the date of grant.

The Company intends that the Plan and any Stock-Based Awards granted hereunder be exempt from the application of Section 409A of the Code or meet the requirements of paragraphs (2), (3) and (4) of subsection (a) of Section 409A of the Code, to the extent applicable, and be operated in accordance with Section 409A so that any compensation deferred under any Stock-Based Award (and applicable investment earnings) shall not be included in income under Section 409A of the Code. Any ambiguities in the Plan shall be construed to effect the intent as described in this Paragraph 8.

9. PERFORMANCE-BASED AWARDS.

The Committee shall determine whether, with respect to a performance period, the applicable Performance Goals have been met with respect to a given Participant and, if they have, to so certify and ascertain the amount of the applicable Performance-Based Award. No Performance-Based Awards will be issued for such performance period until such certification is made by the Committee. The number of Shares issued in respect of a Performance-Based Award determined by the Committee for a performance period shall be paid to the Participant at such time as determined by the Committee in its sole discretion after the end of such performance period, and any dividends (other than stock dividends to be issued pursuant to Section 25 of the Plan) or dividend equivalents that accrue shall only be paid in respect of the number of Shares earned in respect of such Performance-Based Award.

10. EXERCISE OF OPTIONS AND ISSUE OF SHARES.

An Option (or any part or installment thereof) shall be exercised by giving written notice to the Company or its designee (in a form acceptable to the Administrator, which may include electronic notice), together with provision for payment of the aggregate exercise price in accordance with this Paragraph for the Shares as to which the Option is being exercised, and upon compliance with any other condition(s) set forth in the Option Agreement. Such notice shall be signed by the person exercising the Option (which signature may be provided electronically in a form acceptable to the Administrator), shall state the number of Shares with respect to which the Option is being exercised and shall contain any representation required by the Plan or the Option Agreement. Payment of the exercise price for the Shares as to which such Option is being exercised shall be made (a) in United States dollars in cash or by check; or (b) at the discretion of the Administrator, through delivery of shares of Common Stock held for at least six months (if required to avoid negative accounting treatment) having a Fair Market Value equal as of the date of the exercise to the aggregate cash exercise price for the number of Shares as to which the Option is being exercised; or (c) at the discretion of the Administrator, by having the Company retain from the Shares otherwise issuable upon exercise of the Option, a number of Shares having a Fair Market Value equal as of the date of exercise to the aggregate exercise price for the number of Shares as to which the Option is being exercised; or (d) at the discretion of the Administrator, in accordance with a cashless exercise program established with a securities brokerage firm, and approved by the Administrator; or (e) at the discretion of the Administrator, by any combination of (a), (b), (c) and (d) above or (f) at the discretion of the Administrator, by payment of such other lawful consideration as the Administrator may determine. Notwithstanding the foregoing, the Administrator shall accept only such payment on the exercise of an ISO as is permitted by Section 422 of the Code.

The Company shall then reasonably promptly deliver the Shares as to which such Option was exercised to the Participant (or to the Participant's Survivors, as the case may be). In determining what constitutes "reasonably promptly," it is expressly understood that the issuance and delivery of the Shares may be delayed by the Company in order to comply with any law or regulation (including, without limitation, state securities or "blue sky" laws) which requires the Company to take any action with respect to the Shares prior to their issuance. The Shares shall, upon delivery, be fully paid, non-assessable Shares.

11. PAYMENT IN CONNECTION WITH THE ISSUANCE OF STOCK GRANTS AND STOCK-BASED AWARDS AND ISSUE OF SHARES.

Any Stock Grant or Stock-Based Award requiring payment of a purchase price for the Shares as to which such Stock Grant or Stock-Based Award is being granted shall be made (a) in United States dollars in cash or by check; or (b) at the discretion of the Administrator, through delivery of shares of Common Stock held for at least six months (if required to avoid negative accounting treatment) and having a Fair Market Value equal as of the date of payment to the purchase price of the Stock Grant or Stock-Based Award; or (c) at the discretion of the Administrator, by any combination of (a) and (b) above; or (d) at the discretion of the Administrator, by payment of such other lawful consideration as the Administrator may determine.

The Company shall when required by the applicable Agreement, reasonably promptly deliver the Shares as to which such Stock Grant or Stock-Based Award was made to the Participant (or to the Participant's Survivors, as the case may be), subject to any escrow provision set forth in the applicable Agreement. In determining what constitutes "reasonably promptly," it is expressly understood that the issuance and delivery of the Shares may be delayed by the Company in order to comply with any law or regulation (including, without limitation, state securities or "blue sky" laws) which requires the Company to take any action with respect to the Shares prior to their issuance.

12. RIGHTS AS A SHAREHOLDER.

No Participant to whom a Stock Right has been granted shall have rights as a shareholder with respect to any Shares covered by such Stock Right except after due exercise of an Option or issuance of Shares as set forth in any Agreement, tender of the aggregate exercise or purchase price, if any, for the Shares being purchased and registration of the Shares in the Company's share register in the name of the Participant.

13. ASSIGNABILITY AND TRANSFERABILITY OF STOCK RIGHTS.

By its terms, a Stock Right granted to a Participant shall not be transferable by the Participant other than (i) by will or by the laws of descent and distribution, or (ii) as approved by the Administrator in its discretion and set forth in the applicable Agreement provided that no Stock Right may be transferred by a Participant for value. Notwithstanding the foregoing, an ISO transferred except in compliance with clause

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) above shall no longer qualify as an ISO. The designation of a beneficiary of a Stock Right by a Participant, with the prior approval of the Administrator and in such form as the Administrator shall prescribe, shall not be deemed a transfer prohibited by this Paragraph. Except as provided above during the Participant's lifetime a Stock Right shall only be exercisable by or issued to such Participant (or his or her legal representative) and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of any Stock Right or of any rights granted thereunder contrary to the provisions of this Plan, or the levy of any attachment or similar process upon a Stock Right, shall be null and void.

14. EFFECT ON OPTIONS OF TERMINATION OF SERVICE OTHER THAN FOR CAUSE OR DEATH OR DISABILITY.

Except as otherwise provided in a Participant's Option Agreement, in the event of a termination of service (whether as an Employee, director or Consultant) with the Company or an Affiliate before the Participant has exercised an Option, the following rules apply:

&nbsp;&nbsp;&nbsp;&nbsp;(a) A
 Participant who ceases to be an Employee, director or Consultant of the Company or of an Affiliate (for any reason other than termination
 for Cause, Disability, or death for which events there are special rules in Paragraphs 15, 16, and 17, respectively), may exercise
 any Option granted to him or her to the extent that the Option is exercisable on the date of such termination of service, but only
 within such term as the Administrator has designated in a Participant's Option Agreement.

(b) Except
 as provided in Subparagraph (c) below, or Paragraph 16 or 17, in no event may an Option intended to be an ISO, be exercised later
 than three months after the Participant's termination of employment.

(c) The
 provisions of this Paragraph, and not the provisions of Paragraph 16 or 17, shall apply to a Participant who subsequently becomes
 Disabled or dies after the termination of employment, director status or consultancy; provided, however, in the case of a Participant's
 Disability or death within three months after the termination of employment, director status or consultancy, the Participant or the
 Participant's Survivors may exercise the Option within one year after the date of the Participant's termination of service,
 but in no event after the date of expiration of the term of the Option.

(d) Notwithstanding
 anything herein to the contrary, if subsequent to a Participant's termination of employment, termination of director status
 or termination of consultancy, but prior to the exercise of an Option, the Administrator determines that, either prior or subsequent
 to the Participant's termination, the Participant engaged in conduct which would constitute Cause, then such Participant shall
 forthwith cease to have any right to exercise any Option.

(e) A
 Participant to whom an Option has been granted under the Plan who is absent from the Company or an Affiliate because of temporary
 disability (any disability other than a Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose,
 shall not, during the period of any such absence, be deemed, by virtue of such absence alone, to have terminated such Participant's
 employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly
 provide; provided, however, that, for ISOs, any leave of absence granted by the Administrator of greater than three months, unless
 pursuant to a contract or statute that guarantees the right to reemployment, shall cause such ISO to become a Non-Qualified Option
 on the date that is six months following the commencement of such leave of absence.

(f) Except
 as required by law or as set forth in a Participant's Option Agreement, Options granted under the Plan shall not be affected
 by any change of a Participant's status within or among the Company and any Affiliates, so long as the Participant continues
 to be an Employee, director or Consultant of the Company or any Affiliate.

15. EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR CAUSE.

Except as otherwise provided in a Participant's Option Agreement, the following rules apply if the Participant's service (whether as an Employee, director or Consultant) with the Company or an Affiliate is terminated for Cause prior to the time that all his or her outstanding Options have been exercised:

&nbsp;&nbsp;&nbsp;&nbsp;(a) All
 outstanding and unexercised Options as of the time the Participant is notified his or her service is terminated for Cause will immediately
 be forfeited.

(b) Cause
 is not limited to events which have occurred prior to a Participant's termination of service, nor is it necessary that the
 Administrator's finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant's
 termination of service but prior to the exercise of an Option, that either prior or subsequent to the Participant's termination
 the Participant engaged in conduct which would constitute Cause, then the right to exercise any Option is forfeited.

16. EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR DISABILITY.

Except as otherwise provided in a Participant's Option Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;(a) A
 Participant who ceases to be an Employee, director or Consultant of the Company or of an Affiliate by reason of Disability may exercise
 any Option granted to such Participant to the extent that the Option has become exercisable but has not been exercised on the date
 of the Participant's termination of service due to Disability; and in the event rights to exercise the Option accrue periodically,
 to the extent of a pro rata portion through the date of the Participant's termination of service due to Disability of any additional
 vesting rights that would have accrued on the next vesting date had the Participant not become Disabled. The proration shall be based
 upon the number of days accrued in the current vesting period prior to the date of the Participant's termination of service
 due to Disability.

(b) A
 Disabled Participant may exercise the Option only within the period ending one year after the date of the Participant's termination
 of service due to Disability, notwithstanding that the Participant might have been able to exercise the Option as to some or all
 of the Shares on a later date if the Participant had not been terminated due to Disability and had continued to be an Employee, director
 or Consultant or, if earlier, within the originally prescribed term of the Option.

(c) The
 Administrator shall make the determination both of whether Disability has occurred and the date of its occurrence (unless a procedure
 for such determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall
 be used for such determination). If requested, the Participant shall be examined by a physician selected or approved by the Administrator,
 the cost of which examination shall be paid for by the Company.

17. EFFECT ON OPTIONS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT.

Except as otherwise provided in a Participant's Option Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;(a) In
 the event of the death of a Participant while the Participant is an Employee, director or Consultant of the Company or of an Affiliate,
 such Option may be exercised by the Participant's Survivors to the extent that the Option has become exercisable but has not
 been exercised on the date of death; and in the event rights to exercise the Option accrue periodically, to the extent of a pro rata
 portion through the date of death of any additional vesting rights that would have accrued on the next vesting date had the Participant
 not died. The proration shall be based upon the number of days accrued in the current vesting period prior to the Participant's
 date of death.

(b) If
 the Participant's Survivors wish to exercise the Option, they must take all necessary steps to exercise the Option within one
 year after the date of death of such Participant, notwithstanding that the decedent might have been able to exercise the Option as
 to some or all of the Shares on a later date if he or she had not died and had continued to be an Employee, director or Consultant
 or, if earlier, within the originally prescribed term of the Option.

18. EFFECT OF TERMINATION OF SERVICE ON UNACCEPTED STOCK GRANTS AND STOCK- BASED AWARDS.

In the event of a termination of service (whether as an Employee, director or Consultant) with the Company or an Affiliate for any reason before the Participant has accepted a Stock Grant or a Stock-Based Award and paid the purchase price, if required, such grant shall terminate.

For purposes of this Paragraph 18 and Paragraph 19 below, a Participant to whom a Stock Grant or a Stock-Based Award has been issued under the Plan who is absent from work with the Company or with an Affiliate because of temporary disability (any disability other than a Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not, during the period of any such absence, be deemed, by virtue of such absence alone, to have terminated such Participant's employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly provide.

In addition, for purposes of this Paragraph 18 and Paragraph 19 below, any change of employment or other service within or among the Company and any Affiliates shall not be treated as a termination of employment, director status or consultancy so long as the Participant continues to be an Employee, director or Consultant of the Company or any Affiliate.

19. EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF TERMINATION OF SERVICE OTHER THAN FOR CAUSE, DEATH OR DISABILITY.

Except as otherwise provided in a Participant's Agreement, in the event of a termination of service for any reason (whether as an Employee, director or Consultant), other than termination for Cause, death or Disability for which there are special rules in Paragraphs 20, 21, and 22 below, before all forfeiture provisions or Company rights of repurchase shall have lapsed, then the Company shall have the right to cancel or repurchase that number of Shares subject to a Stock Grant or Stock-Based Award as to which the Company's forfeiture or repurchase rights have not lapsed.

20. EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF TERMINATION OF SERVICE FOR CAUSE.

Except as otherwise provided in a Participant's Agreement, the following rules apply if the Participant's service (whether as an Employee, director or Consultant) with the Company or an Affiliate is terminated for Cause:

&nbsp;&nbsp;&nbsp;&nbsp;(a) All
 Shares subject to any Stock Grant or Stock-Based Award that remain subject to forfeiture provisions or as to which the Company shall
 have a repurchase right shall be immediately forfeited to the Company as of the time the Participant is notified his or her service
 is terminated for Cause.

(b) Cause
 is not limited to events which have occurred prior to a Participant's termination of service, nor is it necessary that the
 Administrator's finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant's
 termination of service, that either prior or subsequent to the Participant's termination the Participant engaged in conduct
 which would constitute Cause, then all Shares subject to any Stock Grant or Stock-Based Award that remained subject to forfeiture
 provisions or as to which the Company had a repurchase right on the date of termination shall be immediately forfeited to the Company.

21. EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF TERMINATION OF SERVICE FOR DISABILITY.

Except as otherwise provided in a Participant's Agreement, the following rules apply if a Participant ceases to be an Employee, director or Consultant of the Company or of an Affiliate by reason of Disability: to the extent the forfeiture provisions or the Company's rights of repurchase have not lapsed on the date of Disability, they shall be exercisable; provided, however, that in the event such forfeiture provisions or rights of repurchase lapse periodically, such provisions or rights shall lapse to the extent of a pro rata portion of the Shares subject to such Stock Grant or Stock-Based Award through the date of Disability as would have lapsed had the Participant not become Disabled. The proration shall be based upon the number of days accrued prior to the date of Disability.

The Administrator shall make the determination both as to whether Disability has occurred and the date of its occurrence (unless a procedure for such determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall be used for such determination). If requested, the Participant shall be examined by a physician selected or approved by the Administrator, the cost of which examination shall be paid for by the Company.

22. EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT.

Except as otherwise provided in a Participant's Agreement, the following rules apply in the event of the death of a Participant while the Participant is an Employee, director or Consultant of the Company or of an Affiliate: to the extent the forfeiture provisions or the Company's rights of repurchase have not lapsed on the date of death, they shall be exercisable; provided, however, that in the event such forfeiture provisions or rights of repurchase lapse periodically, such provisions or rights shall lapse to the extent of a pro rata portion of the Shares subject to such Stock Grant or Stock-Based Award through the date of death as would have lapsed had the Participant not died. The proration shall be based upon the number of days accrued prior to the Participant's date of death.

23. PURCHASE FOR INVESTMENT.

Unless the offering and sale of the Shares shall have been effectively registered under the Securities Act, the Company shall be under no obligation to issue Shares under the Plan unless and until the following conditions have been fulfilled:

---

| | |
|:---|:---|
| a. | The person who receives a Stock Right shall warrant to the Company, prior to the receipt of Shares, that such person is acquiring such Shares for his or her own account, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the person acquiring such Shares shall be bound by the provisions of the following legend (or a legend in substantially similar form) which shall be endorsed upon the certificate evidencing the Shares issued pursuant to such exercise or such grant of a Stock Right: |
|  | "The shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any person, including a pledgee, unless (1) either (a) a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or (b) the Company shall have received an opinion of counsel satisfactory to it that an exemption from registration under such Act is then available, and (2) there shall have been compliance with all applicable state securities laws." |
| b. | At the discretion of the Administrator, the Company shall have received an opinion of its counsel that the Shares may be issued in compliance with the Securities Act without registration thereunder. |

---

24. DISSOLUTION OR LIQUIDATION OF THE COMPANY.

Upon the dissolution or liquidation of the Company, all Options granted under this Plan which as of such date shall not have been exercised and all Stock Grants and Stock-Based Awards which have not been accepted, to the extent required under the applicable Agreement, will terminate and become null and void; provided, however, that if the rights of a Participant or a Participant's Survivors have not otherwise terminated and expired, the Participant or the Participant's Survivors will have the right immediately prior to such dissolution or liquidation to exercise or accept any Stock Right to the extent that the Stock Right is exercisable or subject to acceptance as of the date immediately prior to such dissolution or liquidation. Upon the dissolution or liquidation of the Company, any outstanding Stock-Based Awards shall immediately terminate unless otherwise determined by the Administrator or specifically provided in the applicable Agreement.

25. ADJUSTMENTS.

Upon the occurrence of any of the following events, a Participant's rights with respect to any Stock Right granted to him or her hereunder shall be adjusted as hereinafter provided, unless otherwise specifically provided in a Participant's Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(a) Stock
 Dividends and Stock Splits. If (i) the shares of Common Stock shall be subdivided or combined into a greater or smaller number of
 shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii) additional
 shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such
 shares of Common Stock, each Stock Right and the number of shares of Common Stock deliverable thereunder shall be appropriately increased
 or decreased proportionately, and appropriate adjustments shall be made including, in the exercise, base or purchase price per share
 and in the Performance Goals applicable to outstanding Performance-Based Awards to reflect such events. The number of Shares subject
 to the limitations in Paragraph 3(a) and 4(c) shall also be proportionately adjusted upon the occurrence of such events.

---

| | |
|:---|:---|
| (b) | Corporate Transactions. If the Company is to be consolidated with or acquired by another entity in a Corporate Transaction, the Administrator or the board of directors of any entity assuming the obligations of the Company hereunder (the "Successor Board"), shall, as to outstanding Options, either: (i) make appropriate provision for the continuation of such Options by substituting on an equitable basis for the Shares then subject to such Options either the consideration payable with respect to the outstanding shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity; or (ii) upon written notice to the Participants, provide that such Options must be exercised (either (A) to the extent then exercisable or (B) at the discretion of the Administrator, any such Options being made partially or fully exercisable for purposes of this Subparagraph), within a specified number of days of the date of such notice, at the end of which period such Options which have not been exercised shall terminate; or (iii) terminate such Options in exchange for payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number of shares of Common Stock into which such Option would have been exercisable (either (A) to the extent then exercisable or, (B) at the discretion of the Administrator, any such Options being made partially or fully exercisable for purposes of this Subparagraph) less the aggregate exercise price thereof. For purposes of determining the payments to be made pursuant to Subclause (iii) above, in the case of a Corporate Transaction the consideration for which, in whole or in part, is other than cash, the consideration other than cash shall be valued at the fair value thereof as determined in good faith by the Board of Directors. |
|  | With respect to outstanding Stock Grants, the Administrator or the Successor Board, shall make appropriate provision for the continuation of such Stock Grants on the same terms and conditions by substituting on an equitable basis for the Shares then subject to such Stock Grants either the consideration payable with respect to the outstanding Shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity. In lieu of the foregoing, in connection with any Corporate Transaction, the Administrator may provide that, upon consummation of the Corporate Transaction, each outstanding Stock Grant shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number of shares of Common Stock comprising such Stock Grant (to the extent such Stock Grant is no longer subject to any forfeiture or repurchase rights then in effect or, at the discretion of the Administrator, all forfeiture and repurchase rights being waived upon such Corporate Transaction). |
|  | In taking any of the actions permitted under this Paragraph 25(b), the Administrator shall not be obligated by the Plan to treat all Stock Rights, all Stock Rights held by a Participant, or all Stock Rights of the same type, identically. |
| (c) | Recapitalization or Reorganization. In the event of a recapitalization or reorganization of the Company other than a Corporate Transaction pursuant to which securities of the Company or of another corporation are issued with respect to the outstanding shares of Common Stock, a Participant upon exercising an Option or accepting a Stock Grant after the recapitalization or reorganization shall be entitled to receive for the price paid upon such exercise or acceptance if any, the number of replacement securities which would have been received if such Option had been exercised or Stock Grant accepted prior to such recapitalization or reorganization. |
| (d) | Adjustments to Stock-Based Awards. Upon the happening of any of the events described in Subparagraphs (a), (b) or (c) above, any outstanding Stock-Based Award shall be appropriately adjusted to reflect the events described in such Subparagraphs. The Administrator or the Successor Board shall determine the specific adjustments to be made under this Paragraph 25, including, but not limited to the effect of any, Corporate Transaction and, subject to Paragraph 4, its determination shall be conclusive. |
| (e) | Modification of Options. Notwithstanding the foregoing, any adjustments made pursuant to Subparagraph (a), (b) or (c) above with respect to Options shall be made only after the Administrator determines whether such adjustments would (i) constitute a "modification" of any ISOs (as that term is defined in Section 424(h) of the Code) or (ii) cause any adverse tax consequences for the holders of Options, including, but not limited to, pursuant to Section 409A of the Code. If the Administrator determines that such adjustments made with respect to Options would constitute a modification or other adverse tax consequence, it may in its discretion refrain from making such adjustments, unless the holder of an Option specifically agrees in writing that such adjustment be made and such writing indicates that the holder has full knowledge of the consequences of such "modification" on his or her income tax treatment with respect to the Option. This paragraph shall not apply to the acceleration of the vesting of any ISO that would cause any portion of the ISO to violate the annual vesting limitation contained in Section 422(d) of the Code, as described in Paragraph 6(b)(iv). |

---

&nbsp;&nbsp;&nbsp;&nbsp;(f) Change
 of Control. In the event that the successor corporation refuses to assume or substitute the Stock Right as set forth in this Paragraph
 25, the Participant shall fully vest and become exercisable or earned, if applicable, in each outstanding Stock Right as to which
 it would not otherwise be vested, exercisable or earned. If a Stock Right becomes fully vested and exercisable or earned, as applicable
 in lieu of assumption or substitution in the event of a Corporate Transaction or Change of Control, the Administrator shall notify
 each Participant in writing or electronically that (i) the Stock Right shall be fully vested and exercisable for a period determined
 by the Administrator, and all outstanding Stock Rights shall terminate upon the expiration of such period and (ii) any Stock Rights
 to which shares or other payment shall be due shall be paid out immediately prior to the Corporate Transaction or Change of Control
 as if fully vested or earned. For the purposes of this paragraph, the Stock Right shall be considered assumed if, following the Corporate
 Transaction or Change of Control, the assumed Stock Right confers the right to purchase or receive, for each Share subject to a Stock
 Right immediately prior to the Corporate Transaction or Change of Control, the consideration (whether stock, cash, or other securities
 or property) received in the Corporate Transaction or Change of Control by holders of Common Stock for each share of Common Stock
 they hold on the effective date of the transaction (and if holders are offered a choice of consideration, the type of consideration
 chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if such consideration received
 in the Corporate Transaction or Change of Control is not solely common stock of the successor corporation or its parent, the Administrator
 may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise (or payout or
 vesting, as applicable) of the Stock Right, for each Share subject to the Stock Right, to be solely common stock of the successor
 corporation or its parent equal in Fair Market Value to the per share consideration received by holders of Common Stock in the Corporate
 Transaction or Change of Control.

26. ISSUANCES OF SECURITIES.

Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares subject to Stock Rights. Except as expressly provided herein, no adjustments shall be made for dividends paid in cash or in property (including without limitation, securities) of the Company prior to any issuance of Shares pursuant to a Stock Right.

27. FRACTIONAL SHARES.

No fractional shares shall be issued under the Plan and the person exercising a Stock Right shall receive from the Company cash in lieu of such fractional shares equal to the Fair Market Value thereof.

28. WITHHOLDING.

In the event that any federal, state, or local income taxes, employment taxes, Federal Insurance Contributions Act withholdings or other amounts are required by applicable law or governmental regulation to be withheld from the Participant's salary, wages or other remuneration in connection with the issuance of a Stock Right or Shares under the Plan or for any other reason required by law, the Company may withhold from the Participant's compensation, if any, or may require that the Participant advance in cash to the Company, or to any Affiliate of the Company which employs or employed the Participant, the statutory minimum amount of such withholdings unless a different withholding arrangement, including the use of shares of the Company's Common Stock or a promissory note, is authorized by the Administrator (and permitted by law). For purposes hereof, the fair market value of the shares withheld for purposes of payroll withholding shall be determined in the manner set forth under the definition of Fair Market Value provided in Paragraph 1 above, as of the most recent practicable date prior to the date of exercise. If the Fair Market Value of the shares withheld is less than the amount of payroll withholdings required, the Participant may be required to advance the difference in cash to the Company or the Affiliate employer.

29. NOTICE TO COMPANY OF DISQUALIFYING DISPOSITION.

Each Employee who receives an ISO must agree to notify the Company in writing immediately after the Employee makes a Disqualifying Disposition of any Shares acquired pursuant to the exercise of an ISO. A Disqualifying Disposition is defined in Section 424(c) of the Code and includes any disposition (including any sale or gift) of such Shares before the later of (a) two years after the date the Employee was granted the ISO, or (b) one year after the date the Employee acquired Shares by exercising the ISO, except as otherwise provided in Section 424(c) of the Code. If the Employee has died before such Shares are sold, these holding period requirements do not apply and no Disqualifying Disposition can occur thereafter.

30. TERMINATION OF THE PLAN.

The Plan will terminate on March 29, 2028, the date which is ten years from the earlier of the date of its adoption by the Board of Directors and the date of its approval by the shareholders of the Company. The Plan may be terminated at an earlier date by vote of the shareholders or the Board of Directors of the Company; provided, however, that any such earlier termination shall not affect any Agreements executed prior to the effective date of such termination. Termination of the Plan shall not affect any Stock Rights theretofore granted.

31. AMENDMENT OF THE PLAN AND AGREEMENTS.

The Plan may be amended by the shareholders of the Company. The Plan may also be amended by the Administrator; provided that any amendment approved by the Administrator which the Administrator determines is of a scope that requires shareholder approval shall be subject to obtaining such shareholder approval including, without limitation, to the extent necessary to qualify any or all outstanding Stock Rights granted under the Plan or Stock Rights to be granted under the Plan for favorable federal income tax treatment as may be afforded ISOs under Section 422 of the Code and to the extent necessary to qualify the Shares issuable under the Plan for listing on any national securities exchange or quotation in any national automated quotation system of securities dealers. Other than as set forth in Paragraph 25 of the Plan, the Administrator may not without shareholder approval reduce the exercise price of an Option or cancel any outstanding Option in exchange for a replacement option having a lower exercise price, any Stock Grant, any other Stock-Based Award or for cash. In addition, the Administrator not take any other action that is considered a direct or indirect "repricing" for purposes of the shareholder approval rules of the applicable securities exchange or inter-dealer quotation system on which the Shares are listed, including any other action that is treated as a repricing under generally accepted accounting principles. Any modification or amendment of the Plan shall not, without the consent of a Participant, adversely affect his or her rights under a Stock Right previously granted to him or her, unless such amendment is required by applicable law or necessary to preserve the economic value of such Stock Right. With the consent of the Participant affected, the Administrator may amend outstanding Agreements in a manner which may be adverse to the Participant but which is not inconsistent with the Plan. In the discretion of the Administrator, outstanding Agreements may be amended by the Administrator in a manner which is not adverse to the Participant. Nothing in this Paragraph 31 shall limit the Administrator's authority to take any action permitted pursuant to Paragraph 25.

32. EMPLOYMENT OR OTHER RELATIONSHIP.

Nothing in this Plan or any Agreement shall be deemed to prevent the Company or an Affiliate from terminating the employment, consultancy or director status of a Participant, nor to prevent a Participant from terminating his or her own employment, consultancy or director status or to give any Participant a right to be retained in employment or other service by the Company or any Affiliate for any period of time.

33. SECTION 409A.

If a Participant is a "specified employee" as defined in Section 409A of the Code (and as applied according to procedures of the Company and its Affiliates) as of his separation from service, to the extent any payment under this Plan or pursuant to the grant of a Stock-Based Award constitutes deferred compensation (after taking into account any applicable exemptions from Section 409A of the Code), and to the extent required by Section 409A of the Code, no payments due under this Plan or pursuant to a Stock- Based Award may be made until the earlier of: (i) the first day of the seventh month following the Participant's separation from service, or (ii) the Participant's date of death; provided, however, that any payments delayed during this six-month period shall be paid in the aggregate in a lump sum, without interest, on the first day of the seventh month following the Participant's separation from service.

The Administrator shall administer the Plan with a view toward ensuring that Stock Rights under the Plan that are subject to Section 409A of the Code comply with the requirements thereof and that Options under the Plan be exempt from the requirements of Section 409A of the Code, but neither the Administrator nor any member of the Board, nor the Company nor any of its Affiliates, nor any other person acting hereunder on behalf of the Company, the Administrator or the Board shall be liable to a Participant or any Survivor by reason of the acceleration of any income, or the imposition of any additional tax or penalty, with respect to a Stock Right, whether by reason of a failure to satisfy the requirements of Section 409A of the Code or otherwise.

34. INDEMNITY.

Neither the Board nor the Administrator, nor any members of either, nor any employees of the Company or any parent, subsidiary, or other Affiliate, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with their responsibilities with respect to this Plan, and the Company hereby agrees to indemnify the members of the Board, the members of the Committee, and the employees of the Company and its parent or subsidiaries in respect of any claim, loss, damage, or expense (including reasonable counsel fees) arising from any such act, omission, interpretation, construction or determination to the full extent permitted by law.

35. CLAWBACK.

Notwithstanding anything to the contrary contained in this Plan, the Company may recover from a Participant any compensation received from any Stock Right (whether or not settled) or cause a Participant to forfeit any Stock Right (whether or not vested) in the event that the Company's Clawback Policy as then in effect is triggered.

36. GOVERNING LAW.

This Plan shall be construed and enforced in accordance with the law of the State of Delaware.